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Project Summary 
Caspases are a major contributor to the apoptotic pathway. We intended to investigate the 
role of caspases, namely caspase-6, which has not been fully characterized in Amyotrophic 
Lateral Sclerosis (ALS). We utilized quantitative PCR (qPCR) to determine caspase-6 
mRNA expression in nervous tissue from neocortex as well as ntg SOD1
G93A
; caspase-6
-/-
 
gastrocnemius muscle (pnd 35), ntg SOD1
G93A
; caspase-6
+/+
 gastrocnemius muscle (pnd 35), 
and compared this with purified primary motorneurons, microglia-enriched and astrocyte-
enriched cultures from primary E12 spinal cord tissue. No significant differences in caspase-
6 mRNA expression were detected in the sample types examined compared to nervous tissue.  
We decided to investigate if caspase-6 protein levels were altered in a transgenic mouse 
model of ALS. We measured pro caspase-6 levels in tg and ntg SOD1
G93A
 lumbar spinal cord 
at pnd 70, pnd 120, and pnd endstage (150-160 days). We found that pro caspase-6 showed a 
tendency towards an increase with the progression of ALS, yet this was is not at statistically 
significant levels. To further elucidate the role of caspase-6 during ALS disease progression, 
we developed a cross-breeding program to produce a SOD1
G93A
 mouse colony deficient for 
caspase-6. The loss of motor function is a phenotypic indicator of ALS disease onset and 
progression in transgenic SOD1
G93A 
mice. Motor function and behavioural analysis 
paradigms were used to assess the effect of caspase-6 deletion on functional defects and the 
lifespan of SOD1
G93A
; caspase-6 colony. Surprisingly, we found that caspase-6 deficiency 
does not protect limb function, endurance, and motility in SOD1
G93A
 mice and has no effect 
on body weight. We recorded the lifespan of SOD1
G93A
; caspase-6
-/-
 mice to examine the 
effect of caspase-6 deletion during disease progression. Non-parametric analysis revealed 
that genetic deletion of caspase-6 did not increase survival in tg SOD1
G93A
; caspase-6
-/-
 mice 
compared to tg SOD1
G93A
; caspase-6
+/+
 littermates, in fact it significantly decreased survival. 
It has been hypothesized that caspase-6 may have a role in the degeneration in skeletal 
muscle that occurs prior to the onset of motorneuron degeneration in the spinal cord (Graham 
et al. 2006). We wanted to determine if motor endplates from hindlimb skeletal muscle 
showed any morphological changes in caspase-6 deficient mice compared to ntg SOD1
G93A 
mice. Our findings showed no obvious signs of variation. We also compared weight and 
morphology of gastrocnemius muscle in SOD1
G93A 
mice and showed that deletion of 
caspase-6 does not affect muscular atrophy in this mouse model for ALS.  
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Our initial hypothesis was that deletion of caspase-6 would protect neurons against cell death 
and therefore improve the phenotype in the SOD1
G93A
 ALS mouse model. However we found 
the opposite were true and that deletion of caspase-6 enhanced disease progression and 
decreased lifespan. We hypothesize that caspase-6 is protective during ALS pathogenesis as 
the degenerative phenotype is worse when caspase-6 is removed, however further work is 
required to fully characterise the role of caspase-6. 
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Chapter 1: Introduction 
1.1 Motorneuron diseases 
Motor neuron disease (MND) is a progressive neurodegenerative disease identified by the 
degeneration of motor neurons within the central nervous system (CNS). Upper motor 
neurons (UMN) and lower motor neurons (LMN) are attacked, which leads to progressive 
muscle weakness, atrophy, and paralysis. Motorneuron disease can be further characterized 
into four forms: Amyotrophic Lateral Sclerosis (ALS), Progressive Bulbar Palsy (PBP), 
Progressive Muscular Atrophy (PMA), and Primary Lateral Sclerosis (PLS) 
(mndassociation.org).  
Neurodegenerative disorders are becoming increasingly prevalent and carry a significant 
economic burden due to the care-intensive nature of the disease. As a growing health 
problem, a more in depth understanding of MND etiology and pathogenesis is salient. 
1.2 Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis, also referred to as Lou Gehrig‟s disease, is a fatal progressive 
motorneuron disease that has no cure. The disease was first described by French physician 
and neurobiologist, Jean-Martin Charcot and his colleagues when conducting studies of the 
spinal cord between 1865-1869 (Kumar et al. 2011). The term “amyotrophic lateral sclerosis” 
would not be given by Charcot until 1874, but his observations of the disease have virtually 
remained unaltered to present day (Kumar et al. 2011). In the United States, the disease is 
more commonly known as Lou Gehrig‟s disease in honour of a New York Yankees American 
baseball player who was diagnosed with the disease in 1936 and who later died of ALS in 
1941 at the age of 37. Diagnosis of the disease can be difficult for physicians as the 
symptoms that are associated with ALS are also common in other types of diseases, for 
instance myasthenia gravis or Kennedy‟s disease in which patients also experience muscle 
weakness.  Because there is no specific test for ALS, physicians are forced to rely on a formal 
set of criteria for diagnosis (Hardiman et al. 2011). Most manifestations of typical forms of 
the disease can be seen first in the limbs as muscle weakness and muscular atrophy, and 
sometimes slurred speech and dysphagia (Kiernan, 2009; Gordon, 2013).  Other symptoms of 
the disease, although more rare, may include frontotemporal dementia (FTD) and loss of 
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bulbar function (Kiernan et al. 2011). In most cases, patients die as a result of respiratory 
failure. As ALS is restricted to motorneuron dysfunction the senses of sight, touch, smell, 
hearing, and tastes are unaffected. In most cases, bladder and eye muscles are not affected.  
The median duration of survival for ALS patients after diagnosis are 1-5 years with the 
average age of onset between 50-60 years (Rowland and Schneider, 2001).  As the most 
common motorneuron disease, ALS has a prevalence of 1-2 per 100,000 people/year and an 
incidence of 6-8 per 100,000 people/year in the United States (Pasinelli and Brown, 2006). In 
1994, a consensus was held by the World Federation of Neurology to determine the diagnosis 
criteria known as the El Escorial criteria (Miller et al. 1999). These disease parameters were 
revised in 1998 for recognition of laboratory testing and re-named the Airlie House criteria 
(Miller et al. 1999). Based on the degree of certainty of diagnosis, the criteria stated that 
clinical evaluation must show degeneration of LMN and/or UMN in the same topographical 
anatomical region of the CNS (Hardiman et al. 2011). Patients that are described to have 
these criteria, discounting other similar diseases, are diagnosed with ALS. 
Currently there is only one Food and Drug Administration (FDA)-approved treatment that is 
available to ALS patients called Riluzole. Unfortunately, Riluzole extends the life of ALS 
patients by just 3-6 months and is only beneficial for the alleviation of associated symptoms 
of the disease (Miller et al. 2007; Bellingham, 2011). Although the mechanism of action is 
not clearly understood, Riluzole has been shown to protect cultured neurons from anoxic 
damage, toxic effects of glutamic-acid-uptake inhibitors, and from the toxic factor in the CSF 
of patients with ALS (Doble, 1996). There are no drugs present on the market that reverse the 
disease.  
1.3 Amyotrophic Lateral Sclerosis disease pathology  
ALS is a multifaceted disease that involves many pathophysiological mechanisms.  A 
complex interaction between genetic and molecular pathways has been widely studied for the 
treatment of ALS (Pasinelli and Brown, 2006; Vucic and Kiernan, 2009; Hardiman et al. 
2011; Chen et al. 2013). Although, there have been many studies on the cause of ALS, there 
is little conclusive data on the cause, probable factors, and cure for ALS (Hardiman et al. 
2011). It has been proposed that the degeneration of motorneurons is primarily caused by a 
cellular death process known as apoptosis, but other cellular dysfunctions have been studied 
to explain the progression and onset of ALS, for instance mitochondrial dysfunction (De Vos 
et al. 2008; Magrane and Manfredi, 2009; Shi et al. 2009). Mediators of motorneuron death 
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are known to include: oxidative stress, mitochondrial dysfunction and excitotoxicity, caspase-
mediated death, intracellular aggregates, axonal transport dysfunction, and growth factor 
deficiency (Pasinelli and Brown, 2006).  
As a complex disease with many factors, ALS occurs in two distinct forms, sporadic (sALS) 
and familial (fALS). The familial form of ALS accounts for approximately 10% of cases with 
patients showing a genetic-linkage (Pasinelli and Brown, 2006; Chen et al. 2013). This is far 
less than the sporadic (sALS) form which occurs in 90% of cases where patients have no 
family history of the disease (Pasinelli and Brown, 2006; Byrne, Bede et al. 2011; Hardiman, 
van den Berg et al. 2011) In fALS, two members of the family must be diagnosed with ALS 
for sporadic occurrence to be omitted (Byrne, Bede et al. 2011).  Important breakthroughs in 
the understanding of the familial form (fALS) of ALS have been beneficial for the 
identification of genetic factors associated with the disease (Tan, W. et al. 2014). One of the 
most studied genes with many known mutations associated with ALS, superoxide dismutase 
1 (SOD1) accounts for more than 20% of all fALS cases (Tan, W. et al. 2014). 
1.3.1 Spinal Cord Structure 
ALS involves dysfunction and degeneration of motorneurons of the brainstem and spinal 
cord. Spinal nerves transmit sensory information from the muscles and CNS, communicating 
motor commands necessary for voluntary movement. Death of both upper and lower 
motorneurons is implicated in ALS. The death of upper motorneurons, located in the motor 
cortex in the brain, leads to hyperexcitability of reflexes and appearance of pathological 
reflexes, as well as spasticity (Dadon-Nachum et al. 2011).  Death of lower motorneurons in 
the brainstem and spinal cord, particularly in the ventral horn, present symptoms that include 
muscular weakness and atrophy, followed by progressive paralysis (Dadon-Nachum et al. 
2011).  Mouse models are commonly used to study ALS, which provides direct comparison 
to humans for clinical relevance. This is due to the similarity of human and mouse spinal cord 
structure. Humans and mice have 31 pairs of spinal nerves. Because the ventral horn of the 
lumbar spinal cord is rich in motorneurons, the study of this area is salient to understanding 
one of the first clinical symptoms of ALS, loss of fine motor control of the lower limbs. 
Motorneurons are abundant in the ventral and lateral horns of the spinal cord in mice. 
Differences between mouse and human spinal cord organization include a lack of grey matter 
surrounding white matter in the mouse spinal cord.  Another major difference is that motor 
tracts within the spinal cord of humans are not restricted to the ventral horns. This provides a 
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significant level of variability in the positioning of the corticospinal tracts between humans 
and animal models. Lateral columns contain corticospinal bundles in primates and humans, 
while these bundles can be found in the dorsal columns of rodents (Brown, 1971). Although 
there are some differences in the structure of spinal cord between murine models and 
humans, the complexity of the nervous system is comparable for clinical purposes.  
 
 
                                                Mouse Lumbar Spinal Cord 
 
 
Figure 1.1 Mouse lumbar spinal cord structure 
The mouse lumbar spinal cord includes the dorsal horn (DH) which is located posteriorly and 
the ventral horn (VH) which consist of motorneurons that innervate the lower limbs. 
Connected to the ventricular system is the central canal (cc) which contains cerebrospinal 
fluid (CSF). Image adapted from Tokyo Metropolitan Institute for Neuroscience website 
(http://tmin.igakuken.or.jp). 
 
1.3.2 Genetic mutations implicated in ALS disease pathology 
In recent years, accumulating data on genetic and non-genetic causes of ALS has emerged. 
Several genetic mutations that have been identified as causative of ALS, many of which have 
been discovered in the last 3-5 years (Al-Chalabi, Jones et al. 2012). Due to similar clinical 
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phenotypes of sALS and fALS cases, there is a need for an understanding of how genetic 
factors are involved. It is understood that the disease displays a Mendelian pattern of 
inheritance in fALS.  The discovery of many of the genes with mutations in fALS cases 
occurred via linkage analysis. Genetic linkage studies look for the tendency for genetic 
markers to be inherited together as a consequence of physical proximity on a chromosome. 
The genetic basis of ALS was unknown until 1989 when the first locus (ALS1) associated 
with dominant familial adult-onset ALS was identified. The gene at this locus was identified 
as SOD1 (Rosen et al. 1993). Since this poignant discovery, linkage studies have given rise to 
10 loci discovered in association with high-risk ALS (Leblond et al. 2014). The most 
commonly mutated in adult onset ALS are: SOD1, FUS, TARDBP (known as TDP-43), and 
C9ORF72 (Leblond et al. 2014). With this information, studies to investigate the role of 
fALS-genes in sALS have been on-going. In less than 2% of sALS cases, mutations in SOD1, 
FUS, and TARDBP have been discovered (Anderson and Al-Chalabi, 2011). In a more recent 
study, the most common mutation, in the C9ORF72 gene, was found in 6% of sALS cases 
worldwide and 15-20% cases in Sweden and Finland (Rademakers, R. et al. 2013). More 
information is needed to fully understand the implications of genetic mutations associated 
with the etiology of ALS. Further study of genetic mutations in ALS could be the key to 
disease prevention and treatment by inhibition of mutations in high-risk genes. 
1.3.3 Superoxide Dismutase One 
In ALS, mutations in the SOD1 gene account for over 2% of all cases (Rosen et al. 1993). In 
1993, a gene encoding enzyme, SOD1, was discovered and has been linked to over 170 
genetic defects that are responsible, in part, for facilitating the premature degeneration of 
motorneurons (Pasinelli and Brown, 2006; Al-Chalabi, Jones et al. 2012; Leblond et al. 
2014). The gene is composed of five exons encoding a 153 amino acid metalloenzyme, which 
is referred to as Cu/Zn superoxide dismutase 1 (Saccon et al. 2013).  Highly conserved across 
species, SOD1 is ubiquitously expressed and the deleterious effect of mutant SOD1 is 
considered to be due to a toxic gain of function (Fridovich, 1995). Gurney et al. have 
developed a reliable mouse model that overexpresses human mutant SOD1. This widely used 
mouse model has a point mutation that was originally identified in ALS patients at codon 93, 
replacing Glycine with Alanine, and is referred to as SOD1
G93A
.  With this mutation, mice 
and rats develop progressive motorneuron degeneration and closely mimic the phenotype 
seen in ALS patients (Gurney et al. 1994). SOD1 binds copper and zinc ions to form a 
homodimer which, as a dismutase, removes dangerous superoxide radicals by metabolizing 
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them to molecular oxygen and hydrogen peroxide (Saccon et al. 2013). This is necessary as a 
defence against reactive oxygen species (ROS), which is toxic. When mutant SOD1 protein is 
misfolded, motorneuron degeneration may be caused by impaired axonal transport, protein 
aggregate production, inhibited heat-shock proteins, and inhibition of anti-apoptotic proteins 
(Pasinelli and Brown, 2006).  
1.3.4 “Dying-back” hypothesis 
In ALS animal models, evidence points to neuronal dysfunction before clinical manifestation 
of the disease. Muscle weakness is generally one of the first symptoms of the disease in 
humans, prompting clinical evaluation and eventual diagnosis for ALS patients. Is has been 
hypothesized that motor unit loss and associated muscle function may precede motorneuron 
death. This phenomenon known as the “dying-back” hypothesis shows a distal to proximal 
axonal degeneration and is a common pattern seen in degenerative disorders in the peripheral 
and central nervous system (Fischer et al. 2004; Dadon-Nachum et al. 2011). In a study 
completed by Fischer et al., the axon, cell body, and neuromuscular junction (NMJ) was 
examined at multiple timepoints to show the spatiotemporal progression of motorneuron 
pathology in the SOD1
G93A
 mouse (Fisher et al. 2004). The results showed an earlier 
denervation of axons at the NMJ at post natal day (pnd) 47, motor axons in the ventral root 
decreasing between pnd 47 and 80, and loss of α-motor neuron cell bodies in the lumbar 
spinal cord after pnd 80. The findings from this study may represent an example of a “dying-
back” motor neuropathy, where the distal axon degenerates before the onset of symptoms, 
before neuronal degeneration (Fischer et al. 2004). Several mechanisms have been suggested 
for the “dying-back” pattern leading to progressive loss of motorneurons in ALS. One theory 
suggests an aggregation of insoluble complexes, possibly mutant SOD1, which causes an 
insufficient maintenance of the distal axon. As a result, axonal abnormalities that inhibit 
retrograde transport allow for selective damage to motor neurons which may prevent the cell 
body from receiving target-derived neurotropic factors (Dadon-Nacum et al. 2011). 
According to the “dying-back” hypothesis, if cell body degradation occurs later in the disease 
compared to axonal degeneration, a new focus should be set on motor neuron terminals to 
prevent or delay the progression of ALS.  
 1.4 Apoptosis 
For many diseases, including ALS, apoptosis has been investigated as a possible contributor 
to disease onset and progression. Apoptosis is a process that is often referred to as programed 
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cell death (PCD) (Fusch and Stellar, 2011). It is a cell regulation process that occurs in 
developing and adult tissue and is necessary for homeostasis. The process of apoptosis is 
regulated by caspases which are cysteine aspartic proteases that cleave at specific sites to 
generate active fragments, leading to cell death (Graham et al. 2011). Apoptosis can be 
described by its morphology which includes membrane blebbing, cell rounding, cytoskeletal 
collapse, fragmentation, cytoplasmic condensation, nuclear pyknosis, chromatin 
condensation/fragmentation, and formation of membrane-enveloped apoptotic bodies 
(Ghavami et al. 2014). Multiple stress stimuli known as activators of apoptosis include: 
Deoxyribonucleic acid (DNA) damage, circulating cytotoxins, and inflammation (Youle and 
Strasser, 2008; Yeretssian, Correa et al. 2011).  
1.4.1 Intrinsic Apoptotic Pathway 
The intrinsic apoptotic pathway plays a pivotal role in normal development and homeostatic 
control of adult tissue. As a result, the role of this apoptotic pathway is important in the study 
of diseases where excessive or insufficient cell death may play a part in disease pathogenesis. 
The intrinsic apoptotic pathway has been proposed as a mechanism of motorneuron death in 
ALS due to mitochondrial dysfunction (Cozzolino and Carri, 2012; Vehviläinen et al. 2014). 
An event is referred to as mitochondrial outer membrane permeabilization (MOMP) is the 
central key to the intrinsic apoptosis pathway because it allows for the release of cytochrome 
c from the cytosol (Marino et al. 2014). Cytochrome c binds to the adaptor protein, apoptotic 
protease activating factor-1 (Apaf-1) and recruits caspase-9 to form the apoptosome which 
initiates apoptosis (Fuchs and Stellar, 2011). Activation of MOMP can be triggered by 
several factors. One such factor includes the upregulation of transcriptional factors like p53 
and ogliomerization of BH3-only proteins (BAX or BAK) in the outer mitochondrial 
membrane (Cory and Adams, 2011). This can stimulate MOMP to form supramolecular 
channels that allow for the flow of soluble proteins from the intermembrane space of the 
mitochondria (Cory and Adams, 2011). When MOMP is activated, other pro-apoptotic 
factors are also co-released with cytochrome-c. These include:  1. Apoptosis-inducing factor 
(AIF) 2. Endonuclease G (EndoG) and 3. Second mitochondria-derived activator of caspase 
(SMAC) (Marino et al. 2014). Because MOMP activates multiple cell death pathways 
through the release of these factors, it is considered the “point-of-no-return” in the intrinsic 
apoptosis pathway. For example, both AIF and EndoG can promote caspase-independent 
nuclear fragmentation (Kroemer and Martin, 2005). 
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1.4.2 Cysteine-dependent, Aspartate-Specific Proteases 
Caspases are key regulators of the cell death process in apoptosis and also play a part in non-
apoptotic processes such as synaptic plasticity, axon guidance, cell differentiation, 
inflammatory processes, and proliferation (Martinon and Tschopp, 2004; Block and Hong, 
2005; Uribe et al. 2012).  Caspases are proteolytic enzymes, with an affinity to the aspartate 
and cysteine in their active center, that propagate the apoptotic process through a proteolytic 
cascade. Caspases are present in the cytoplasm as zymogens, which are inactive enzyme 
precursors. These latent zymogens contain an N-terminal prodomain. The prodomain is 
surrounded by the region that forms two subunits containing the catalytic domain. Caspases 
are heterotetrameric complexes, and include two small and two large subunits with the initial 
proteolytic activation at specific aspartate sites (Marino et al. 2014). Cleavage at the C-
terminal, separating the small subunit from the rest of the molecule, culminates an active 
caspase which autocatalyticlly cleaves off the prodomain (Los et al. 1999). Caspases can be 
classified into two different groups, initiator and effector caspases. Initiator caspases exist as 
monomers in cells and are self-activated through proximity-induced dimerization, whereas 
effector caspases are activated by proteolytic processing by and initiator caspase (Shi, 2004). 
Initiator caspases (caspases-8 and caspases-9) are activated first by upstream signals (Los et 
al. 1995). Effector caspases (caspase-3, caspase-6, caspase-7) are then activated (Fuchs and 
Stellar, 2011; Ghavami et al. 2009). Initiator caspases have long prodomains that bind to 
large adaptors to promote caspase activation, whereas effector caspases have a short 
prodomain and execute apoptosis after initiator caspases have been activated (Fuchs and 
Stellar, 2011). Initiator caspases are activated by external cell death triggering molecules. 
Caspase-8 is activated by molecules such as Tumour Necrosis Factor alpha (TNF-α), TNF-
related apoptosis-inducing ligand (TRAIL), and Fas whereas caspase-9 is generally activated 
due to internal stress (starvation and cellular dysfunction) which triggers a release of 
cytochrome c from the mitochondria (Fuchs and Steller, 2011). After the addition of the 
adaptor protein, Apaf-1, this facilitates the formation of the apoptosome complex. Activation 
of the apoptosome propagates the activation of other caspases which initiates a proteolytic 
caspase cascade and eventual death of the cell (Friedlander, 2003).  
Caspase-6 is activated through proteolytic cleavage, as are the effector caspases caspase-3 
and caspase-7. Caspase-6 has a catalytic cysteine located at position 163 of the p20 subunit 
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and is comprised of a short pro-domain, large subunit (p20), short linker region, and a small 
subunit (p10) (Klaiman et al 2009). Generated from the zymogen by cleavage at the D23 
residue, the active form of caspase-6 is a heterotetramer which consists of two p20 and two 
p10 subunits and is cleaved between the pro-domain and the p-20 subunit and at the D179 
and D193 residues subunits (Srinivasula, S.M. et al. 1996). 
There is very little information on the mechanisms of caspase-6 activation, but it is often 
considered downstream of caspase-3 activity (Cohen, G.M., 1997; Slee, E.A. et al. 2001; 
Adrain, C. et al. 2005; Guerrero et al. 2008). In addition, it has been reported that inhibitor of 
apoptosis protein (IAP) that inhibit active caspase-3, caspase-7, and caspase-9 do not inhibit 
caspase-6 (Deveraux and Roy et al. 1998). Cowling et al. showed that in cytochrome c-
induced apoptosis in vivo, caspase-6 demonstrates upstream activity and is a major activator 
of caspase-8 (Cowling and Downward, 2002).  
Although the mechanism remains unclear, subsequent work has provided support for the idea 
that caspase-6 can self-activate in vivo, despite being an effector caspase (Wang et al. 2010). 
It has been shown that caspase-6 has the ability to self-activate, but does not induce cell death 
in HEK293T cells (Klaiman et al. 2009). In a study completed by Edgington et al. an 
activity-based probe that labels executioner caspases-3,-6,-7 in vivo was utilized to 
demonstrated that caspase-6 can bind substrates even in the absence of cleavage of the 
proenzyme and does not require active caspase-3 or caspase-7 in certain conditions 
(Edgington L.E. et al. 2012).  
 It has also been shown that active caspase-6 has the ability to cleave initiator caspase-2 and 
caspase-8, but it is not clear how this process is engaged (Slee et al. 1999; Inoue et al. 2009). 
The effector caspases are considered phylogenetically similar, but caspase-6 does not share 
the same substrate recognition sequence as caspase-3 and caspase-7 (Thornberry, N.A et al. 
1997). Furthermore, caspase-6 is exceptional in that the inhibitor of the apoptosis family of 
proteins that inhibit caspase-3 and caspase-7 do not inhibit caspase-6 (Deveraux, Q.L. et al. 
1997). In addition, studies have shown that caspase-6 can be activated in the absence of 
caspase-3 or caspase-7 activity and can significantly precede the activation of caspase-3 
(LeBlanc et al. 1999; Doostzadeh-Cizeron et al. 2000; Allsopp et al. 2000).  
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1.4.3 Caspase-6, alternative and potential roles 
The potential therapeutic role of caspase-6 in neurodegenerative disease has become a 
research focus due to novel findings implicating caspase-6 in Alzheimer‟s disease (AD) 
(LeBlanc, 2013) and Huntington disease (HD) (Waldron-Roby et al. 2012). It has been 
suggested that caspase-6 may have an upstream role in the pathogenesis of neurodegenerative 
diseases (Graham et al. 2011) and may be a possible therapeutic target in neurodegenerative 
disease, although this remains controversial due to recent studies (Harris et al., 2010) that 
have published conflicting data. The evidence of caspase-6 activation as an early event in AD 
has become a focus in recent research due to its association with pathologies that define AD 
(LeBlanc, 2013). It has been proposed that inhibition of caspase-6 as a novel target for the 
disease may be beneficial for preventing AD progression (LeBlanc, 2013) and demonstrates a 
high level of relevancy since caspase-6 is activated in both sporadic and familial forms of AD 
(Guo et al. 2004; Albrecht et al. 2007, 2009).  
In vivo studies are important to understanding the clinical manifestations and phenotypical 
effects of caspase-6 deficiency for neurodegenerative disease. In one study, caspase-6 
deficient mice (Casp6-/-) showed age-dependent behavioral and region-specific 
neuroanatomical changes, indicating that caspase-6 deficiency may have an effect in brain 
regions that are involved in neurodegenerative diseases, for instance the cortex in AD and the 
striatum in HD (Uribe et al. 2012). Active caspase-6 was discovered to be present in brains of 
patients that did not have apoptotic morphology in patients with AD, which suggests an 
alternative earlier function for caspase-6 other than an effector caspase (Albrecht et al. 2007, 
Graham et al. 2010). Caspase-6 activation has also been shown to correlate with lower 
cognitive performance in AD (Albrecht et al. 2007; Ramcharitar et al. 2013; LeBlanc, 2014). 
Other alternative roles include caspase-6 involvement in B-lymphocyte activation. Watanabe 
et al. demonstrated the regulatory role of caspase-6 in B-lymphocyte activation and 
differentiation into plasma cells via modification of cell cycle entry in vivo, which gives new 
insight to how to eliminate dysregulated B cells in autoimmune disorders and cancers 
(Wantanabe et al. 2008). In addition, caspase-6 may have a role in regulating inflammatory 
processes in vivo (Berta et al. 2014). 
Axon degeneration has been implicated in neurodegeneration and has been linked to the 
pathogenesis of AD (Kanaan et al. 2013) and ALS (Fischer et al. 2004). In naturally 
occurring cell death, axons are removed along with their cell bodies, often as a result of 
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competition for limiting amounts of trophic factors like NGF (Raff et al., 2002). It has been 
suggested axon degeneration occurs due to the distinct activation of caspase-6 (Nikolaev et 
al. 2009; Vohra et al. 2010), although conflicting data demonstrates that active caspase-3 is 
required before the activation of caspase-6 to initiate axon degeneration (Slee et al. 1999; 
Walsh et al. 2008; Simon et al 2012.) To investigate the potential role of caspase-6 in axons 
Uribe et al., discovered that neuronal growth factor (NGF) withdrawal-induced axonal 
degeneration could be prevented in caspase-6 null sympathetic cervical ganglion neurons in 
vitro (Uribe et al. 2012). Other studies using sympathetic cervical ganglion neurons and 
dorsal root ganglion (DRG) have shown that withdrawal of trophic support and dynactin I 
dysfunction result in caspase-6 dependent axonal degeneration (Vohra et al. 2010). Other 
insults to neurons including DNA damage with etoposide, ER stress with tunicamycin, and 
microtubule destabilization with vinblastine  
In contradiction, a study completed by Simon et al. demonstrated that NGF withdraw 
utilizing DRG explants showed that small amounts of active caspase-3 are required to 
stimulate caspase-6 activation and subsequent axon degeneration in vitro (Simon et al. 2012). 
It is possible that this may provide and explanation for previous studies which may have 
misinterpreted caspase-6 and its direct involvement in axonal degeneration due to failed 
detection of small amounts of active caspase-3. Additional experiments involving genetic 
deletion of caspase-3 in vivo demonstrated more complete axon protection than deletion 
of caspase-6 in in vitro sensory neuron cultures (Simon et al. 2012). These results and 
conflicting data from previous studies highlight the need to identify and characterize the 
potential alternative functions of caspase-6 in neurodegenerative diseases like AD and ALS.  
Evidence of caspase activation has been previously identified and evaluated in the ALS 
mouse model, SOD1 (Pasinelli et al. 2000; Li et al. 2000). Several experimental observations 
indicate that mutant SOD1 toxicity involves sequential activation of caspase-1 and caspase-3 
in transgenic mice and in cellular models of ALS (Pasinelli et al. 2000; Li et al. 2000; 
Geugan et al. 2003). It has been hypothesized that caspase-1 activity contributes to an 
inflammatory pathway causing early astrocytosis in mutant SOD1 mice (Pasinelli et al. 
2000). Caspase-3 has also been implicated as a mediator of ALS in SOD1
G93A
 mice due to 
prominent activation in astrocytes which may be direct targets for SOD1-mediated toxicity 
and subsequent increased disease progression (Pasinelli et al. 2000). Until recently much of 
the research has yet to focus on the understanding of caspase-6, due to the hypothesis that 
upstream caspases promote a cascade to downstream caspases. The lack of understanding for 
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caspase-6 mechanisms and biology in neuronal death has propagated novel research in 
transgenic mouse models for ALS (Graham et al. 2006). We expect caspase-6 to be upstream 
of other caspases and to demonstrate an alternative role from its previously named effector 
title in the SOD1
G93A
 mouse model. 
 
1.5 Aims of this study 
The aim of this project was to assess the role of caspase-6 in amyotrophic lateral sclerosis-
mediated neurodegeneration in an animal model of ALS, the SOD1
G93A
 mouse. A growing 
need exists for a therapeutic treatment paradigm that can be used to treat patients with ALS. 
Caspases are a major contributor to the apoptotic pathway and have been implicated in 
neurodegenerative disease pathology (Pasinelli et al. 1998, 2000; Uribe et al. 2012). Due to a 
lack of understanding of the role of caspases in ALS disease progression, an investigation of 
the implications of caspase-6 deficiency on survival, motor function, and axon viability may 
identify possible targets for therapeutic intervention. We intend to investigate the role of 
caspases, namely caspase-6, which has not been fully characterized in motorneurons. We 
hypothesize that the ablation of caspase-6 in an ALS mouse model, the SOD1
G93A
 mouse, 
may be protective against axonal degeneration and delay disease onset and progression. 
 To investigate the role of apoptosis and caspase-6 in ALS, our aims were: 
 To characterize pro caspase-6 mRNA expression in skeletal muscle and motorneurons  
 To investigate caspase-6 expression levels during disease progression in the ALS 
mouse model, SOD1
G93A
 
 To generate a tg SOD1G93A mouse deficient in caspase-6 (tg SOD1G93A; caspase-6-/-) 
 To determine the effect of caspase-6 deficiency on disease onset and symptom progression 
in the SOD1 mouse model. Rotarod®, grip strength, PaGE, stride length, and body weight 
will be used to determine disease progression.  
 To investigate if caspase-6 deficiency alters the lifespan of SOD1G93A mice 
 To elucidate the effect of genetic deletion of caspase-6 on axonal/motor endplates at 
pnd endstage in tg and ntg SOD1
G93A
; caspase-6
-/- 
mice. 
 
 
  
29 
 
 
 
 
 
 CHAPTER 2 
Materials and Methods 
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2.1 Chemical List 
Table 2.1 List of Chemicals 
Chemical Name Catalogue No. Manufacturer Molarity 
Protease inhibitor  P2850 Sigma-Aldrich  
Sodium-Pentobarbitone 267543 Vetoquinol  
Phosphate buffered saline 17-516Q Lonza  
Jung Tissue Freezing Medium 
(OTC) 
14020108926 
Leica 
Microsystems 
 
Paraformaldehyde p6148-500g Sigma-Aldrich  
Staurosporine 
ALX-380-014-
M001 
ENZO Life 
Sciences 
 
DMSO D8418 Sigma-Aldrich  
OptiPrep Density Gradient 
Medium 
D1556-250ml Sigma-Aldrich 
 
 
2.2 Equipment  
Table 2.2 List of Equipment 
Equipment Manufacturer Model Application 
Rotarod 
(R)
 Steolting Ugo Basile Motor Function 
Grip Strength Meter Steolting Ugo Basile Motor Function 
Cryostat Leica 3050 S Cryo sectioning 
NanoDrop Thermo Scientific NanoDrop 2000c RNA measurement 
Thermal Cycler MJ Research PTC-200 PCR 
Light Cycler Roche Lightcycler 2.0 PCR 
Fluorescent microscope Nikon TE 200-S IHC 
Semi-dry transfer cell BioRad TransBlot SD Western blotting 
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Chemiluminescent imager Fujifilm LAS 4000 Western blotting 
Plate reader Tecan GENios Western blotting 
 
Table 2.3: Dissection equipment 
Tools Manufacturer Application 
Vannas Sisscors VWR Micro dissection 
Scissors VWR Micro dissection 
Forcepts VWR Micro dissection 
Dissection microscope Olympus (SZ51) Micro dissection 
 
2.3 Ethical Approval 
Ethical approval was received for this project from the RCSI Research Ethics Committee 
(Ref: REC447bbb). A licence was obtained from the Irish Government, so that procedures 
could be legally carried out. This was granted under the Cruelty to Animals Act, 1976 (Ref: 
B100/4415). A record of sacrificed animals was kept and annual reports were submitted to 
the Department of Health and Children. 
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2.4 Animals  
 
Table 2.4: Mouse strains used for this project 
 
Animals Genotypes Source Application 
SOD1
 G93A
 
 
 
Transgenic (Tg/
 G93A
) 
 
Non-Transgenic (ntg)  
 
 
 
 
The Jackson Laboratories, 
Bar Harbor, Maine, USA  
 
 
 
 
Motor function 
 
Primary 
neuronal 
cultures 
 
Cross breeding 
 
Caspase-6  
 
knockout  
(Caspase-6 -/-) 
 
heterozygous 
(Caspase-6 +/-)  
 
wild type  
(Caspase-6 +/+) 
 
The Jackson Laboratories, Bar 
Harbor, Maine, USA 
 
Motor function 
 
Cross breeding 
 
2.4.1 SOD1
G93A
 mouse model 
 
SOD1
G93A 
mice C57B6.Cg-Tg (SOD1G93A) 1Gur/J mice were purchased from The Jackson 
Laboratory (Bar Harbor, Maine) and maintained in house. SOD1
G93A
 breeding pairs were 
generated on a congenic C57BL/6 background and were inbred for eight generations in the 
Biomedical Research Facility at RCSI.  SOD1
G93A
 mice were housed and bred during this 
study in accordance with the “working with ALS mice, preclinical testing and colony 
management”, guidelines provided by The Jackson Laboratories (Leitner, 2009). No more 
than 5 mice were housed per experimental cage. No more than 3 females were housed per 
breeding cage and were separated to individual cages after evidence of pregnancy was 
identified. Multiple litters were acquired from several breeding cages to acquire the animals 
numbers needed for each genotype. Litter size ranged from 4-10 mice per litter and female 
breeders were replaced after 6 months of age for optimum breeding. Mice were housed at 
constant temperature (22 °C) on a 12 h light/dark cycle (07:00 h on, 19:00 h off), with ad 
libitum food and water available. Transgenic and ntg SOD1
G93A
 genotypes were confirmed by 
tail snip DNA extraction and PCR. 
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2.4.2 Caspase-6
-/-
 gene deficient mice 
 
Caspase-6 deficient mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) 
and maintained in house. Heterozygous mice were backcrossed to a C57 BL/6 background 
for 10 generations before purchase. After weaning on postnatal day (pnd) 28, pups from 
litters of the same generation were housed in groups of three to five per cage and maintained 
at 21±1 °C on a 12-h light/dark cycle (07:00 h on; 19:00 h off), with ad libitum access to food 
and water.  No more than 5 mice were housed per experimental cage. No more than 3 females 
were housed per breeding cage and were separated to individual cages after evidence of 
pregnancy was identified. Multiple litters were acquired from several breeding cages to 
acquire the animals numbers needed for each genotype. Litter size ranged from 4-10 mice per 
litter and female breeders were replaced after 6 months of age for optimum breeding. 
Transgenic and ntg SOD1
G93A
 genotypes were confirmed by tail snip DNA.  
 
 
2.4.3 SOD1
 G93A
 Caspase-6
 -/-
 cross breeding 
The SOD1
 G93A
; caspase-6
-/-
 colony was generated by cross-breeding male tg SOD1
 G93A
 mice 
with caspase-6
/-
 females generating the F1 generation of SOD1
 G93A
;caspase-6
+/-
 mice. From 
the F1 generation, ntg SOD1
G93A
; caspase-6
+/-
 females were crossed with tg SOD1
 
G93A
;caspase-6
+/-
 males. The F2 colony generated 6 genotypes, ntg SOD1
 G93A
;caspase-6
+/+
, 
ntg SOD1
 G93A
;caspase-6
+/-
, ntg SOD1
 G93A
;caspase-6
-/-
, tg SOD1
 G93A
;caspase-6
+/+
, tg SOD1
 
G93A
;caspase-6
+/-
 and tg SOD1
 G93A
;caspase-6
-/-
, with all genotypes generated equal in 
incidence and in a ratio consistent with Mendelian inheritance. The SOD1
 G93A
; caspase-6
-/-
 
colony cross-breeding was confirmed by using tail snip DNA for SOD1
G93A
 and caspase-6 
genes. All six genotypes did not differ in development, fertility, or size to SOD1
 G93A 
mice. 
Multiple litters were acquired from several breeding cages to acquire the animals numbers 
needed for each genotype since heterozygous mice were not utilized.  
 
2.5 Genotyping- DNA extraction 
In order to confirm the genotypes of the SOD1
 G93A
 and SOD1
 G93A
; Caspase-6 cross-
breeding colony, a tail snip DNA polymerase chain reaction (PCR) was utilized for analysis. 
A 2 millimetre section of tail was removed from the mice of interest and placed into an 
Eppendorf tube and stored at -20 ºC until further processing. DNA was extracted with the use 
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of a High Pure PCR Template Kit (Roche) according to the manufacturer‟s instructions.  The 
PCR was performed on the eluted DNA and the samples were run on a 2% agarose gel 
alongside a 100 bp ladder. Bands were visualized via SYBR Safe DNA gel stain (7%) (Life 
Technologies). Transgenic SOD1 samples were identified by the presence of a 236 bp band 
and the wild type allele determined by the presence of a 324 bp band. The presence of a single 
620 bp fragment denotes Caspase
+/+ 
and a single 340 bp fragment denotes the deleted allele 
in Caspase
-/-
 mice. A fragment at both 620 bp and 340 bp denotes Caspase
+/-
 genotype.  
 
2.5.1 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) refers to the in vitro amplification of DNA. Oligonucleotide 
primers were commercially synthesized to be complementary to the 5 prime (5‟) and 3 prime 
(3‟) ends of the DNA sequence of interest. Samples were run in the thermal cycler with a 
annealing program that was preset. Each primer sequence required a variation of the standard 
cycles. Target DNA is denatured at 95 ºC for 10 minutes prior to primer annealing, which 
occurs between 50-60 ºC according to the individual primer properties. This facilitates the 
annealing of specific complementary primers to corresponding DNA sequences. Raising the 
temperature to 72 ºC allows Taq Polymerase to produce a complementary second strand of 
DNA by exponential elongation of the annealed primers. This process results in the 
production of double stranded copies of the specific DNA sequence of interest.  
2.5.2 Agarose Gel Electrophoresis 
After the PCR was performed with the extracted DNA, the samples were run on a 2% agarose 
gel alongside a 100 bp ladder. Transgenic SOD1 samples were identified by the presence of a 
236 bp band and the wild type allele determined by the presence of a 324 bp band. The 
presence of a single 620 bp fragment denotes Caspase
+/+ 
and a single 340 bp fragment 
denotes the deleted allele in Caspase
-/-
 mice. A fragment at both 620 bp and 340 bp denotes 
Caspase
+/-
 genotype.  
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Table 2.5: SOD1
G93A
 primers  
SOD1 forward primer 0042  
(SOD1 transgenic) 
5‟ CTAGGCCACAGAATTGAAAGATCT 3‟  
 
SOD1 reverse primer 0043  
(SOD1 transgenic) 
5‟ GTAGGTGGAAATTCTAGCATCATC 3‟  
 
SOD1 forward primer 0113  
(wildtype allele-specific) 
5‟ CATCAGCCCTAATCCATCTGA 3‟  
 
SOD1 reverse primer 0114  
(wildtype allele-specific) 
5‟ CGCGACTAACAATCAAAGTGA 3‟  
 
 
 
Table 2.6: SOD1
G93A
 Reagents/Components 
 
Reaction Component Volume (µl) Final Concentration 
ddH2O 3.52 - 
10x AB PCR Buffer  0.84 0.70 X 
25 mM MgCl2 0.48 1.00 mM 
2.5 mM dNTP  0.96 0.20 mM 
20 µm SOD1 primer 0042 0.45 0.75 mM 
20 µm SOD1 primer 0043 0.45 0.75 mM 
20 µm SOD1 primer 0113 0.80 1.33 mM 
20 µm SOD1 primer 0114 0.80 1.33 mM 
Taq DNA Polymerase (Invitrogen) 0.04 0.02 U/ul 
DNA Loading Dye 1.66 0.69 mM 
DNA 2.00 - 
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Table 2.7: SOD1
G93A
 Cycling Conditions 
 
Step  Temp ºC Time Note 
1 95 3 min - 
2 95 30 sec - 
3 60 30 sec - 
4 72 45 sec Repeat steps 2-4 for 35 cycles 
5 72 2 min  
6 4 - hold 
 
 
Table 2.8: Caspase-6 primers  
Caspase-6 (common) 
 
5‟ CTCCACGGCCTAATGCAGTTCCTGG 3‟ 
Caspase-6 (wildtype allele-specific) 
 
5‟ CTGAGGGGCGGAGCACCTTTGCTG 3‟ 
Caspase-6 (mutant allele-specific) 
 
5‟ GCCTTCTTGACGAGTTCTTCTGAGG 3‟ 
 
Table 2.9: Caspase-6 Reagents/Components 
 
Reaction Component Volume (µl) Final Concentration 
ddH2O 4.32 - 
10x Kappa Rxn Buffer (B) 1.20 1.00 X 
2.5 mM dNTP 0.96 0.20 mM 
20 µm Caspase-6 primer (common) 0.60 1.00 µM 
20 µm Caspase-6 primer (wildtype) 0.60 1.00 µM 
20 µm Caspase-6 primer (mutant) 0.60 1.00 µM 
KAPATaq DNA Polymerase 0.06 5 U/ul 
DNA Loading Dye 1.66 0.69 mM 
DNA 2.00 - 
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Table 2.10: Caspase-6 Cycling Conditions 
 
Step  Temp ºC Time Note 
1 94 3 min - 
2 94 30 sec - 
3 58 30 sec - 
4 72 45 sec Repeat steps 2-4 for 35 cycles 
5 72 2 min  
6 4 - hold 
 
2.6 Motor Function Analysis 
Motor Function performance included Rotarod (Steogling, Italy), grip strength (Ugo Basile), 
PaGE (Paw Grip Endurance), stride length, and weight measurement. Analysis was 
performed in the Behavioural Testing Room located in the Biomedical Research Facility 
(BRF) in RCSI. Tests were recorded in the same sequence twice weekly and the average was 
used for data analysis. All of the mice used were trained to use the motor function equipment 
from pnd 70. Prior to performance analysis, each strain of mice was age, sex, and litter 
matched, with the exception of ntg SOD1
G93A
; caspase-6 
+/+
 and tg SOD1
G93A
; caspase-6 
+/+
 
control groups (Ludolph, 2010). A five minute rest period was given between each test to 
ensure maximum ability per recording. 
 
2.6.1 Rotarod  
 
The Rotarod test provides a measurement of forelimb strength. Parameters for the Rotarod 
test were set to accelerating rotations per minute (RPM) from 5-42 RPM over a 180 second 
time frame. Mice were placed on a rotating bar with separation panels and were required to 
remain on the accelerating bar until they dropped to a magnetic plate below that would record 
the endpoint of the measurement. The mice were trained to remain on the bar for 10 days 
prior to experimental data recording. 
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2.6.2 Grip Strength 
 
Grip strength meter is a sensitive and accurate method to detect the onset and progression of 
symptoms in SOD1
G93A
 mice (Weydt et al. 2003; Brooks and Dunnett, 2009). The grip 
strength meter (Ugo Basile, Italy) measures forelimb strength and the force applied (g) to 
resist the involuntary backward movement when a mouse is pulled by its tail. The mice 
instinctively grasp a trapeze shaped bar when they are dragged across it, recording the force. 
Grip strength meter analysis was followed Rotarod
(R)
 analysis with a resting period of at least 
5 minutes between both. The mice were given 3-4 attempts to gain the maximum grip 
strength recording. Mice were trained to grasp the bar for 10 days prior to experimental data 
recording. 
 
2.6.3 PaGE  
 
The PaGE test is used to measure the strength of the forelimbs and hindlimbs. Loss of 
function in the limbs is an indication of disease onset and progression. The PaGE test requires 
the mouse to use both fore and hindlimbs to hang upside down on a mesh metal grate for as 
long as possible or a maximum of 60 seconds.   
2.6.4 Stride Length 
 
The stride length test analyses motor function integrity in the hindlimbs by measuring 
changes in gait. The hind feet are painted with a non-toxic paint and mice are trained to walk 
on a strip of paper. Three consecutive paw prints on the left and right foot are measured and 
averaged for analysis. This test is completed once a week from pnd 63 to endstage. 
 
2.6.5 Body Weight 
 
Weight analysis is used as an indication of disease onset and progression. Weight for each 
mouse was measured on a standard weighing scale and recorded in the afternoon for 
consistency. The weight for each mouse was taken twice weekly and averaged. One factor in 
defining endstage status is determined with a 20% reduction in body weight (Kieran, Kalmar 
et al. 2004; Kieran, Hafezparast et al. 2005; Knippenberg, Thau et al. 2010). 
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2.6.6 Righting Reflex 
 
ALS disease end stage can be determined by the loss of righting reflex. This occurs when a 
mouse has reached the point where when it is placed on its side it fails to right itself after 30 
seconds (Ludolph, Bendotti et al. 2010). This method of characterizing the end stage 
timepoint (which occurs around pnd 150-160) is the most consistent determination of end 
stage ALS in SOD1
G93A
 mice (Leitner, 2009). 
 
2.7 Time-mating procedure 
 
C57/BL/6 female mice were time mated at 8 weeks old to produce E12 embryos. The time 
mating procedures were adapted to alter the female‟s oestrous cycles using the Whitten Effect 
(Green 1976). Male mice were housed individually for 3 days prior to breeding. Females 
were housed at 4-5 animals per cage, for 2 days, which brings the females into their oestrous 
cycles simultaneously upon exposure to male androgens or bedding from male cages. The 
female mouse oestrous cycle occurs over 4-5 days, with ovulation on day 3, therefore 
yielding the maximum number of pregnancies within a short time. Females were added to the 
male cages on Monday morning and removed on Wednesday afternoon, to facilitate 
nocturnal breeding. The females were checked at 7 am for the presence of a copulatory plug 
and records were taken to estimate E0. Female mice were also weighed prior to time mating 
and at the E7 and E12 stages of pregnancy. 
 
2.8 Transcardial Perfusion 
 
Transcardial perfusion in mice was carried out with Phosphate Buffered Saline (PBS) to 
remove blood from tissues of interest. Mice were given i.p. injection of sodium 
pentobarbitone (Dolethal®; Vetoquinol, Buckingham, United Kingdom) (40 mg/kg) and 
placed in a separate cage from littermates until anaesthetic took effect. When animal was 
unconscious the pinch reflex was used to ensure complete anaesthesia. The ribs and 
diaphragm were cut away to expose the heart. A 26 gauge needle and syringe filled with 1x 
PBS was placed into the left ventricle of the heart and the right atrium was cut at the same 
time as the intracardial perfusion commenced.  To ensure that each animal was completely 
perfused, 10-20ml of 1x PBS was used.  After the perfusion was complete, the spinal cord 
was dissected and microdissected into thoracic and lumbar sections by cutting at the 
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theracolumbar junction. This area can be noted by a bulge in the spinal cord. Muscle tissue 
was post-fixed in 4% paraformaldehyde-PBS (7.4 pH) for 20 minutes at room temperature, 
washed with PBS for 5 minutes, then transferred into 30% sucrose overnight (until the tissue 
sank to bottom of cryotube). Tissue was air dried and mounted in Jung (OTC) tissue freezing 
medium (Leica Microsystems, Nussloch, Germany). Dissected spinal cord and skeletal 
muscle were snap frozen using liquid nitrogen in cryotubes and stored at -80
o
C.  
2.9 Immunohistochemistry 
Muscle sections were stained with alpha-bungarotoxin (Molecular Probes, 1:10,000), which 
binds with high affinity to the α-subunit of the nicotinic acetylcholine receptor (AChR) of 
neuromuscular junctions, for 20 minutes at room temperature. After rinsing, muscle sections 
were post-fixed in 4% paraformaldehyde (PFA) for 10 minutes. Sections were rinsed 
thoroughly and cover slipped for analysis under a fluorescent microscope.   
 
Table 2.11: Molecular Probes Used for Immunoblotting 
 
 
 
 
2.10 Microscopy 
Sections were analysed with a Nikon TE200-S fluorescence microscope. Images were 
captured using the Wasabi and Spot imaging software and saved as TIFF files. 
2.11 Cell Culture 
 
NSC-34 (motorneuron/neuroblastoma hybrid) cell line was provided by the Cashman 
laboratory (Cashman et al. 1992), and GL-261(astrocytoma) and BV-2 (immortalized 
microglia) cell lines were purchased from the American Type Culture Collection (ATCC).  
The ATCC contains a large collection of microbial stocks, including microbes containing 
mammalian DNA segments. NSC-34 cells were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum, 2mM L-glutamine, 100 
Antibody Name 
Catalogue 
number 
Antibody type Manufacturer Dilution 
α-Bungarotoxin B-13422 Alexa Fluor 488 
Life 
Technologies 
1:10,000 
  
41 
 
units/ml Penicillin and 0.1% Streptomycin.  GL-261 and BV-2 cell lines were maintained in 
Roswell Park Memorial Institute medium (RPMI) supplemented with (10% Fetal Bovine 
Serum, 2mM L-glutamine, 100 units/ml Penicillina and 0.1 mg/ml Streptomycin). 
 
2.12 Western Blotting  
 
2.12.1 Sample Preparation for tissue 
Spinal cord was dissected from SOD1
G93A
 and SOD1
G93A
; caspase-6 mice at pnd 70, pnd 90, 
pnd 120, and pnd endstage (150-160 days) and snap frozen until homogenate processing. 
Samples were homogenized in Radioimmunoprecipitation assay (RIPA) lysis buffer (Tris-Cl 
pH7.4, NaCl, Sodium Dodecyl Sulfate Polyacrylamide (SDS), (Sodium Deoxycholate, Triton 
x100) with an IKA T-25 Basic Ultra-Turrax homogenizer and incubated on ice for 20 
minutes. The samples were then centrifuged at 13,000 g for 20 minutes at 4 ºC to remove any 
debris resulting in a clear supernatant which was stored at -80 until protein quantification. 
2.12.2 Sample Preparation for cell lines 
NSC-34, GL-261, and BV-2 cell lines were trypsinized and washed once in PBS. The PBS 
was removed and the pellet was re-suspended in RIPA lysis buffer, volume dependent on cell 
pellet size. Samples were then triturated approximately 20 times each with a p200 pipette to 
resuspend the pellet. The tubes were left on ice to lyse for 20 minutes. Following this, the 
samples were centrifuged at 13,000 g for 20 minutes at 4
 o
C. The supernatant was removed 
for protein quantification. Samples were stored at -80
 o
C. 
 
2.12.3 Protein Quantification 
To measure the total protein concentration of brain and spinal cord homogenates a 
bicinchoninic acid (BCA) protein quantification kit was used (Uptima). To determine protein 
concentrations a BSA standard was used to generate a standard curve. In this protein assay, 
sterile flat bottomed 96 well plates were used and the BSA standard was loaded firstly in 
triplicate (0 µg, 2 µg, 4 µg, 6 µg, 8 µg, 10 µg). Each well was loaded with 2 µl of sample for 
measurement in triplicate. Sodium Chloride (0.9% NaCl) (150 µl) was added to each well.  
In addition, three reagents included in the protein quantification kit (A, B, and C) were mixed 
at a ratio of 25:25:1 and 150 µl added to each well. The BCA assay was incubated at 37ºC in 
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the dark for 30 minutes. Protein concentration were determined by measuring the absorbance 
at 560 nm. The blank background absorbance reading for the 0 µg of BSA was subtracted 
from each sample. Protein samples for western blot were made up to 40 µg of protein in 
laemmli buffer (0.5M Tris-Cl, pH 6.8, 10% SDS, 30% glycerol, 5% β-mercaptoethanol, 
0.012% bromophenol blue) (6x made up to 1x with sample). The samples were boiled at 95 
°C for 5-10 min before being loaded onto an SDS-Page gel. 
Table 2.12:  Stacking gel composition 
 
 
 
 
 
 
 
 
 
Table 2.13:  Resolving Gel Composition 
 
 
 
 
 
 
 
Stacking gel (3 mL) 
Gel percentage 5% Units 
H2O 2.1 mL 
30% Acrylamide  500 μL 
1.0 M Tris-HCl (pH 6.8) 380 μL 
10% SDS 30 μL 
10% APS 30 μL 
TEMED 7 μL 
Resolving gel (5 mL) 
Gel percentage 10% 12% 15% Units 
H2O 1.9 1.6 1.1 mL 
30% bis-/acrylamide  mix 1.7 2.0 2.5 mL 
1.5 M Tris-HCl (pH 8.8) 1.3 1.3 1.3 mL 
10% SDS 50 50 50 μL 
10% APS 50 50 50 μL 
TEMED 5 5 5 μL 
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The Mini-PROTEAN Tetra Electrophoresis System from BioRAD was used to prepare the 
gels. The assembly was arranged to cast a gel that was 1.5 mm in width, 8 cm x 8 cm in 
length and breadth. The resolving gel was left for approximately 20 minutes to allow for 
polymerization. Stacking gel was added and a 10 well-comb was inserted. The gel was then 
left to set for 20 minutes.  
2.12.4 Electrophoresis 
Gels were loaded into the BioRAD electrophoresis system which includes a mounting hold 
unit and two electrodes at each end.  Negatively-charged proteins migrate downwards, toward 
the anode. Samples were normalized to equal volume with laemmli buffer and in equal 
concentration (40 µg).  Samples were then heated for 10 minutes at 95
o
C to denature proteins. 
Electrophoresis buffer (25 mM Tris-Cl, pH 8.3, 250 mM glycine and 0.1% SDS) was added 
to up to the brim of the inner chamber of the BioRad mounting system. Four microliters of 
protein marker (PageRuler, Fermentas, Germany) is added to the last well to determine 
migration and molecular weight. Samples (40 µg) were loaded into the wells and the gels 
were set to run at 80 V to drive the samples through the stacking gel. After clearance of the 
stacking gel (aprox 20 minutes), the voltage was increased to 120 V through the resolving 
gel. Samples were run until the blue bromophenol dye-front reached the bottom of the gel. 
Following gel electrophoresis, the proteins were blotted onto a nitrocellulose membrane using 
the semi-dry transfer method. 
2.12.5 Semi-dry transfer 
Whatman Filter paper was cut to measure 9cmx6cm and 8cmx5cm and nitrocellulose 
membranes (Protran™) were cut to measure 9.5cmx6.5cm. The nitrocellulose membranes 
were activated for 5 minutes in deionised water and then placed in transfer buffer (25 mM 
Tris, 192 mM Glycine, 20% methanol (v/v) and adjusted to pH 8.3). Filter paper was soaked 
in transfer buffer prior to application on the BioRad transfer system. Filter paper was placed 
directly on the anode connected plate and an activated membrane was placed on top of the 
filter paper. The gel was removed from the electrophoresis system and the stacking gel was 
discarded before placing the resolving gel on top of the nitrocellulose membrane. Caution 
was taken to avoid air bubbles between the gel and the membrane. This was followed by two 
more pieces of filter paper on top of the gel. The transfer was run at a constant voltage of 18 
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V for ~60 minutes. Following completion of the transfer, membranes were rinsed in TBS-T 
(15 mM Tris-HCl, 200 mM NaCl, pH 6.8 and 0.1% Tween-20). Immersion in Ponceau Red 
(1% Ponceau S in 5% acetic acid) was used to check the success of the transfer and even 
protein loading across the lanes. The membranes were washed in TBS-T to remove all traces 
of Ponceau Red and blocked for 1-2 hours in 5% low fat milk in TBS-T.  
Table 2.14: Primary Antibodies for Western Blot 
 
 
 
 
 
 
 
 
 
Primary Antibody  Species Manufacturer Dilution Incubation 
Anti-Human SOD1  Human Sigma-Aldrich 1:1,000 2 hours RT 
Anti-caspase-6 Rabbit Cell Signalling (#9762) 1:1,000 Overnight 
cleaved-caspase-6 Goat Santa Cruz (sc-22177) 1:1,000 Overnight 
Cleaved- caspase-3 Rabbit Cell Signalling (#9661) 1:1,000 Overnight 
Anti-beta-actin  Mouse 
Sigma-Aldrich   
(A5441) 
1:5,000 
2 hours RT 
Anti-Tubulin  Rabbit 
Sigma-Aldrich  
(T9026) 
1:5,000 
2 hours RT 
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Table 2.15: Secondary Antibodies for Western Blot 
Secondary 
Antibody  
Manufacturer Dilution Incubation 
Peroxidase 
conjugated goat 
anti-mouse 
Jackson ImmunoResearch 
Laboratories Inc., USA 
1:5,000 2 hours RT 
Peroxidase 
conjugated goat 
anti-rabbit 
Jackson ImmunoResearch 
Laboratories Inc., USA 
1:5,000 2 hours RT 
Peroxidase 
conjugated rabbit 
anti-goat 
Jackson ImmunoResearch 
Laboratories Inc., USA 
1:5,000 2 hours RT 
 
2.12.6 Immunoblotting 
Proteins of interest were detected on the membrane by specific primary antibodies which 
bind to target antigens with high affinity. To minimize non-specific antibody binding, 
membranes were first incubated in blocking buffer for 1 hour at 4 ºC. Primary and secondary 
antibodies were incubated in blocking buffer (5% non-fat dry milk in 0.1% TBS-T). 
Membranes were incubated overnight at 4°C with the primary antibodies listed in Table 2.14. 
Following primary antibody incubation, membranes were washed three times in TBS-T and 
incubated with horseradish peroxidase-conjugated (HRP) secondary antibodies (Table 2.15) 
(1:5000, Jackson ImmunoResearch) at room temperature for 2 hrs. Membranes were 
subjected to an additional three washes in TBS-T before HRP signal detection using 
enhanced chemiluminescence (ECL) detection reagent (Amersham Biosciences, 
Buckinghamshire, UK). Several exposure times were used to accurately detect signal by 
using a Fujifilm LAS 4000 digital imaging system.  An image of the protein marker was also 
captured with the white light. Following the identification of the desired band, membranes 
were incubated with loading control β-Actin or α-Tubulin (pending the success of β-Actin) 
for 2 hrs at room tempature (1:5000, Jackson ImmunoResearch). Membranes were washed 
three times in TBS-T and incubated with HRP secondary antibodies (Table 2.15). Membranes 
received an additional three washes in TBS-T before HRP signal detection using ECL 
detection reagent and multiple exposures were implemented to accurately detect signal using 
the Fujifilm LAS 4000 digital imaging system. 
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2.13 Densitometry  
Densitometry is used to measure protein levels on a western blot. A Fuji LAS 4000 CCD 
system generated the resulting images after the membrane was exposed to 
chemiluminescence. The images were analysed using Image J and Adobe Photoshop 
software. Loading controls included β-Actin or α-Tubulin. Loading control values are 
subtracted for each band to give the loading intensity of individual well. Differences in 
intensity are represented as protein expression relative to control, untreated levels. Each 
sample was run a total of three times (n=3) to control for variance. Due to limited starting 
material and minimizing animal numbers, repeats of this experiment were not performed, 
therefore data analysis was completed using one Western blot for each timepoint. 
 
2.14 OptiPrep  
Time mated C57BL/6 mice were sacrificed at E12 and hysterectomies were performed to 
remove embryos. Motorneuron rich ventral horns of embryonic mouse spinal cords spinal 
cords were removed under sterile conditions and mixed neuronal cultures were prepared 
using an adapted version of previously described protocols (Gingras, Gagnon et al. 2007). 
Ventral horns are micro-dissected following neurogenesis at E10-12. All operations were 
carried out at room temperature. After dissection, the samples were incubated in Solution D 
for 20 mins (Optiprep kit, Sigma-Aldrich) to begin the isolation of total cellular fraction. The 
samples were dissociated by repeated passage through a syringe needle (21 gauge). The 
subsequent suspension was layered over Solution C and centrifuged at 12,000 x g for 10 
minutes to remove all cell debris. The supernatant was discarded and the pellet suspended in 
OptiPrep solution diluted with Solution B to give a 1.06 g/ml solution, equivalent to 5.2 g/50 
ml iodixanol. The re-suspended pellet was layered over the 1.06 g/ml solution and 
centrifuged at 8,000 x g for 15 minutes. The banded cells were collected in the upper layer. 
To pellet the motorneuron fraction, the samples were centrifuged at 7,000 x g for 10 minutes 
for collection. 
2.15 Quantitative reverse transcriptase polymerase chain reaction 
Gastrocnemius muscle was dissected from ntg SOD1
G93A
; caspase-6
-/-
 and ntg SOD1
G93A
; 
caspase-6
+/+
 mice at pnd 35 and homogenized for mRNA extraction. Additionally, primary 
mixed neuronal cultures were prepared from the motorneuron rich ventral horns of embryonic 
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mouse spinal cords via OptiPrep to generate pure motorneurons from C57/BL/6 mice. Total 
RNA was extracted from astrocytoma, microglia, and pure motoneurons and cortical neurons 
extracted from embryonic mouse spinal cord. Real-time quantitative PCR (qPCR) was used 
to determine pro caspase-6 levels. 
2.15.1 Total RNA preparation from tissue 
Gastrocnemius muscle samples were placed in a glass mortar and pestle which was 
previously cooled to -80ºC. Each muscle sample was homogenized individually and the 
mortar and pestle was cleaned between each sample with 100% ethanol to prevent cross-
contamination. Each muscle was weighed and trimmed to a standard weight of 140 mg. To 
prevent the muscle tissue from thawing, the mortar and pestle was placed on ice and liquid 
nitrogen was poured onto the muscle just before grinding the fibrous tissue into into a fine 
powder. The resulting powder was collected into an Eppendorf tube containing RIPA buffer 
and placed on ice until further processing.  
Samples were thawed on ice and homogenized in 800 µL of trizol under the fume hood using 
a needle and syringe or a homogenizer in a glass round bottomed tube. Homogenized samples 
were transferred to an Eppendorf tube and centrifuged at 12,000 x g for 10 minutes at 4 ºC. 
Samples were incubated for 15 minutes at room temperature before adding 200 µL of 
chloroform. The Eppendorf tubes containing Trizol and chloroform were shaken by hand and 
incubated for 3 minutes at room temperature. Samples were centrifuged at 13,000 x g for 15 
minutes at 4 ºC separating the aqueous chloroform, protein and trizol phases. The aqueous 
phase was transferred to a new Eppendorf tube containing 450 µL of isopropanol for RNA 
precipitation. Samples were incubated for a further 10 minutes at room temperature and 
centrifuged again at 16, 000 x g for 15 minutes at 4 ºC. The supernatant was removed leaving 
a pellet of RNA which was washed with 1 mL of 75% ethanol by vortexing the sample and 
centrifugation at 12,000 x g for 5 minutes at 4 ºC. Residual ethanol was allowed to evaporate 
off before re-dissolving the RNA in 30 µL of Diethylpyrocarbonate (DEPC) water (Ambion) 
which is an efficient deactivator of RNase. The RNA product was then incubated at 58 ºC for 
10 minutes at 800 x g, and then stored at -80 ºC until cDNA synthesis. 
2.15.2 Total RNA extraction from tissue 
RNA was extracted using Qiazol extraction and/or RLT-buffer lysis and RNeasy processing 
according to the manufacturer's guidelines (Qiagen, Sussex, UK). cDNA synthesis was 
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performed based on equal amounts of RNA using the Superscript™ II Reverse Transcriptase 
(Invitrogen, California, USA). qPCR analysis was performed using the LightCycler (Roche 
Diagnostics, Basel, Switzerland) and the QuantiTech SYBR Green PCR kit (Qiagen) 
following the manufacturer's recommendations and standard cycles and melting 
temperatures. The sense and antisense primers for glyceraldehyde-3-phosphate 
dehydrogenase (gapdh) were sense 5′-AAC TTT GGC ATT GTG GAA GG-3′, antisense 5′-
ACA CAT TGG GGG TAG GAA CA-3′; forSOD1  5′-TCC CCA GAG ACA TGG AGA 
AC-3′ and 5′-GTC GTG TGG AAG ACA TCA CG-3′. RNA levels were normalized 
to gapdh mRNA expression and expressed as n-fold expression over control.  
2.15.3 RNA quantification 
RNA from tissue samples and cells were assessed for concentration and quality using the 
NanoDrop® ND-1000 spectrophotometer. The NanoDrop® ND-1000 is a full-spectrum 
(220-750nm) spectrophotometer that measures 1μl samples with high accuracy and 
reproducibility. For each sample the following results were recorded: 
 Concentration (ng/μl): sample concentration in ng/μl 
 260/280: ratio of sample absorbance at 260 and 280nm. The ratio of absorbance at 
260 and 280nm is used to assess the purity of DNA and RNA. A ratio of ~1.8 is 
generally accepted as “pure” for DNA; a ratio of ~2.0 is generally accepted as “pure” 
for RNA. Values above 2.2 would indicate the presence of protein whereas values 
below 1.8 would indicate an element of sample degradation. 
 
2.15.4 cDNA synthesis for mRNA 
Total RNA was reverse transcribed to produce cDNA from total RNA and cDNA synthesis 
was carried out in a thermal cycler. A standardized run template was established and used to 
facilitate cDNA synthesis from tissue samples. DNase treatment was carried out to prevent 
carryover of genomic DNA. 2 µg of total RNA from each sample was added to an Eppendorf 
tube containing 1 µL 10 X DNase Buffer, 1 µL DNase I H2O to give a final volume of   10 
µL. Samples were incubated at room temperature for 15 minutes before adding 1 µL EDTA. 
Samples were then heated to 65º C for 8 minutes before the addition of 1 µL random 
hexamers (DN6) and incubated at 65º C for 2 minutes and transferred immediately to ice. A 
mix containing 2 µL H2O, 4 µL 5 X Buffer, 1 µL 0.1 M DTT and 1 µL 10 mM dNTPs was 
added to each tube and samples were heated at 42º C for 2 minutes. 1 µL Superscript II
TM
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Reverse Transcriptase was added to each sample and heated at to 42º C for 50 minutes 
followed by      75º C for 10 minutes. Samples were held at 4 ºC when the run was complete 
and were stored at -20 ºC until quantified. Two controls were included in each cDNA 
synthesis run wherein one RNA sample was substituted with H2O and a second sample was 
run without reverse transcriptase (No RT). 
 
2.15.5 Real time quantitative analysis 
Quantitative reverse transcriptase PCR (RT-qPCR) measures the relative number of mRNA 
transcripts of a gene in comparison to a control (beta-actin) transcript. A Lightcycler 2.0 from 
Roche Diagnostic using glass capillaries was used to measure mRNA expression by 
fluorescence. A master mix solution containing 10 µL of SYBR Green, 1 µL of forward and 
reverse primer mix (25 µM) and 7 µL of dH2O was added to each cDNA sample (2 µL) at 4 
ºC. Primers were reconstituted and stored at a concentration of 100 µM. RNA free water (2 
µL) was added to the glass capillary tubes followed by 18 µL of the RNA samples. RT-qPCR 
experiments included two controls, the first control contained control cDNA and the second 
contained DNA/RNA free water as a substitute for cDNA. Control samples were treated 
under the same conditions. Lightcycler capillary tubes were centrifuged at 600 x g for 10 
seconds prior to loading into the Lightcycler. A programme was determined for each mRNA 
in which the melting temperature and cycle number were optimized for each primer set 
according to the template (Table 2.16).  
Table 2.16: Lightcycler program template 
Function Temperature Time Cycles 
Denaturation 95 ºC 10 minutes 1 
Amplification 95 ºC 30 seconds 40 
Amplification 60 ºC 30 seconds 40 
Amplification 72 ºC 30 seconds 40 
Melting Curve 95 ºC 1 second 1 
Melting Curve 65 ºC 15 seconds 1 
Melting Curve 95 ºC 1 second 1 
Melting Curve 40 ºC 1 second 1 
Cooling/ storage 4 ºC 6 hours 1 
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Table 2.17: List of primer sequences 
Target Gene Sense primer (5’) Antisense primer (3’) 
Caspase-6 TGAAATGCTTTAACGACCTCAG GTGGCTTGAAGTCGACACCT 
Beta-actin AGGTGTGATGGTGGGAATG G GGTTGGCCTTAGGGTTCAGG 
GAPDH AAC TTT GGC ATT GTG GAA GG ACA CAT TGG GGG TAG GAA CA 
 
2.16 Statistical analysis 
Motor function was assessed by ANOVA and post-hoc analysis by Tukey‟s multiple 
comparison test. A statistically significant difference between recordings was considered 
when p ≤ 0.05. All data are expressed as mean ± SEM. All behavioral studies were age, 
gender and litter matched and included 12 mice per treatment group or genotype in 
accordance with ALS guidelines for pre-clinical studies (Ludolph, Bendotti et al. 2007; 
Ludolph, Bendotti et al. 2010). Kaplan-Meier survival plots were used to analyse survival 
between colonies.  For Western blot analysis, two-tailed Mann-Whitney U-tests for non-
parametric data or two-tailed student t-tests for normally distributed data sets were used.  
Statistical analysis was performed by PASW statistics version 20 Software (IBM, Dublin, 
Ireland). 
For gene expression analysis via qPCR, fold changes were generated using the Comparative 
CT method which uses the following arithmetic formula to achieve results for relative 
quantification: 2–ΔΔCT 
Relative quantification established the change in expression of caspase-6 relative to the 
nervous tissue reference sample. In the comparative CT method, relative quantity (RQ) of 
other sample types was expressed relative to the reference sample that was used as the basis 
for comparative results. Therefore, the reference was the 1X sample and all other quantities 
were expressed as an n-fold difference relative to the reference. ΔCT was achieved by 
subtracting the endogenous control CT from samples‟ CT, therefore ΔCT = CT (sample) – 
CT (endogenous control). The ΔΔCT was worked out by comparing expression levels 
relative to the reference sample, thus ΔΔCT = ΔCT (sample) - ΔCT (calibrator). Using the 2-
ΔΔCT method, the data presented is the fold change in caspase-6 gene expression normalised 
to the endogenous reference gene β-actin and relative to the nervous tissue sample. 
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Biological and technical replicates were carried out for each sample type, and statistical 
significance was determined using a paired 2-tailed student t-test. Statistical significance was 
set at p-value <0.05.  
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Chapter 3: Caspase-6 expression in motorneurons and during motorneuron 
degeneration in SOD1
G93A
 mice 
3.1 Introduction  
Caspase-dependent apoptosis is a major subject of interest in neurodegenerative research. 
Studies have shown that evidence for apoptotic cell death is present in the form of chromatin 
condensation and reduction in cell size at the onset of symptoms in SOD1
G93A
 mice, as 
compared to wild type littermates (Pasinelli and Houseweart, 2000). Li et al. demonstrated 
that inhibition of caspase-1 and caspase-3 via apoptosis inhibitor zVAD-fmk (z-
benzyloxycarbonyl, fmk-fluoromethylketone) delays disease onset in SOD1
G93A
 mice but has 
no effect on survival, the most clinically relevant aim (Li et al. 2000). Caspase-1 is activated 
before the onset of symptoms whereas caspase-3 is activated at later stages of the disease 
which elucidates motorneuron death at an increased rate (Pasinelli and Houseweart, 2000). 
Additionally, caspase-6 activation has been observed before caspase-3 in excitotoxic models 
in vivo (Ferrer, I. et al. 2000; Henshall et al. 2002). It has also been shown that unlike other 
effector caspases, caspase-6 has the ability to self-activate, but does not induce cell death in 
HEK293T cells (Klaiman et al. 2009). A study completed by Edgington et al. confirmed this 
finding by utilizing an activity-based probe that labels executioner caspases-3,-6,-7 in vivo. 
The results demonstrated that caspase-6 can bind substrates even in the absence of cleavage 
of the proenzyme and does not require active caspase-3 or caspase-7 in certain conditions 
(Edgington L.E. et al. 2012).  
Caspase-6 is widely expressed in the brain (Guo et al. 2004, Albrecht et al. 2007, Graham et 
al. 2010) and peripheral tissues (Singh et al. 2002). Pro caspase-6 is ubiquitously expressed 
as evidenced by study completed by Raina et al. which showed that caspase-6 was found in 
association with senile plaques in almost all cases of AD and was present at low levels in 
neurons in both AD and control cases (Raina et al. 2001).  Increased expression of pro 
caspase-6 seen in human fetal tissue and brains of AD subjects (Raina et al. 2001; Godefroy 
et al. 2013) may contribute to mediator of apoptotic cell death in neurodegenerative disease; 
it is salient to understand what occurs when caspase-6, an effector caspase that is typically 
considered to be downstream of caspase-3, is inhibited in vivo, therefore we decided to 
investigate the role of caspase-6 in the SOD1
G93A
 animal model. 
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3.2 Results 
3.2.1 Caspase-6 mRNA is expressed in motorneurons 
We aimed to explore whether caspase-6 was expressed in motorneurons. We utilized 
quantitative PCR (qPCR) to determine caspase-6 mRNA levels in nervous tissue (neocortex) 
as well as ntg SOD1
G93A
; caspase-6
-/-
 gastrocnemius muscle (pnd 35), ntg SOD1
G93A
; 
caspase-6
+/+
 gastrocnemius muscle (pnd 35),  and compared this with purified primary 
motorneurons, microglia-enriched and astrocyte-enriched cultures from primary E12 spinal 
cord tissue. We were interested in expression of caspase-6 mRNA levels in astrocytes and 
microglia due to the hypothesis that the unregulated activation of these cell types is a 
response to neuronal death in ALS and propagates neuronal injury which may lead to the 
progression of the disease (Hall et al, 1998, Clement et al, 2003, Block and Hong, 2005). It 
has also been shown that caspase-6 is involved in regulation of astrocyte survival in HIV 
neurodegeneration (Noorbakhsh et al. 2010). We were also interested in caspase-6 mRNA 
expression levels in gastrocnemius muscle from ntg SOD1
G93A
; caspase-6 mice due to the 
hypothesis that caspase-6 is implicated in the “dying-back” phenomenon which shows a 
distal to proximal axonal degeneration in the SOD1
G93A 
mouse model (Fischer et al. 2004) 
and may be involved in degeneration of skeletal muscle. Primary mixed neuronal cultures 
were prepared from the motorneuron rich ventral horns of embryonic mouse spinal cords. 
Ventral horns were micro-dissected following neurogenesis at E10-12. Optiprep was used to 
generate purified motorneuron cultures. Total RNA was extracted from neocortex nervous 
tissue, microglia and astrocytes from primary tissue as well as ntg SOD1
G93A
; caspase-6
-/-
 
gastrocnemius muscle, ntg SOD1
G93A
; caspase-6
+/+
 gastrocnemius muscle, and purified 
primary motorneurons. Real-time quantitative PCR (RT-qPCR) was used to determine 
caspase-6 levels in different sample types and expression was normalized to β-Actin. No 
significant differences in caspase-6 mRNA expression were detected in the sample types 
examined compared to nervous tissue. This experiment is based on a single run; therefore a 
repeat of this experiment is necessary due to the lack of sample numbers for these sample 
types/conditions. 
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A)                            
 
 
Figure 3.1: Quantitative PCR analysis of caspase-6 mRNA expression levels  
 
A) Total RNA was extracted from nervous tissue (neocortex) and their caspase-6 mRNA 
expression levels compared to ntg SOD1
G93A
; caspase-6
+/+ 
and ntg SOD1
G93A
; caspase-6
-/-
gastrocnemius muscle (pnd 35) expression levels by real-time quantitative PCR (qPCR). 
Additionally, primary neuronal cultures were prepared from the (motorneuron) rich ventral 
horns of embryonic mouse spinal cords. An optiprep gradient centrifugation step was used for 
the generation of purified motorneurons. Ventral horns were micro-dissected following 
neurogenesis at E10-12 and primary motorneuron, astrocyte and microglia cultures were 
derived from caspase-6
+/+ 
neural tissue. The cell culture lysates were processed to qPCR in 
order to compare caspase-6 expression levels in motorneurons to glial expression. Following 
determination of cell or tissue-specific caspase-6 mRNA expression levels, their values were 
normalized to the individual β-actin expression level. No significant differences in caspase-6 
mRNA expression were detected in each sample type examined compared to nervous tissue. 
A two-tailed t-test (paired) was used to assess statistical significance. Error bars represent the 
standard error of the mean (SEM). 
 
 
Caspase-6 
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3.2.2 Pro-caspase-6 protein levels can be detected by Western blot 
Western blot analysis was carried out to identify the protein levels of pro caspase-6 (36 kDa) 
in non-transgenic (ntg) SOD1
G93A
 lumbar spinal cord homogenate (Figure 3.2). A pro 
caspase-6 antibody (Cell Signalling) was utilized for identification of pro caspase-6. 
Following several attempts, blocking of non-specific binding could not be achieved; however 
the pro caspase-6 band can be identified by the absence of a band in the caspase-6
-/-
 sample 
lane. The antibody reportedly detects both pro caspase-6 (36 kDa) and cleaved caspase-6 (15 
kDa) by Western blotting, however no cleaved caspase-6 could be detected in SOD1
G93A
 
mice. 
A)                                
 
 
Figure 3.2: Pro caspase-6 protein levels can be detected by western blot  
A) Western blot analysis was carried out to identify the expression of pro caspase-6 (36 kDa) 
in non-transgenic ntg SOD1
G93A
 lumbar spinal cord homogenate. Pro caspase-6 is detected as 
a band at 36 kDa which is absent in the caspase-6
-/-
 sample.  
ntg SOD1G93A 
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To further characterize the caspase-6 antibody we performed Western blot analysis of NSC-
34 cells treated with 0.1% Staurosporine (STS) dissolved in dimethlsulfoxide (DMSO) to 
induce apoptosis and DMSO as a control (Figure 3.3). STS is insoluble in water therefore 
DMSO is used as a control. This was carried out to identify if we could detect the active 
form. Pro caspase-6 was again detected in ntg SOD1
G93A
 lumbar spinal cord and NSC-34 cell 
lysates of both treatment groups. As expected, pro caspase-6 was not observed in caspase-6 
-/-
 
lumbar spinal cord. Cleaved caspase-6 could not be detected in the STS-treated samples. We 
conclude that cleaved caspase-6 is not detected by this antibody. Cleaved caspase-3 was 
clearly detected as a band of 19kDa in STS-treated NSC-34 lysates indicating apoptosis was 
induced by STS treatment but not by DMSO in the NSC-34 cells. 
 
A) 
 
 
Figure 3.3: Detection of caspase-6 in Staurosporine treated NSC-34 cells 
A) Western blot analysis of NSC-34 cells treated with 0.1% Staurosporine (STS) to induce 
apoptosis and dimethlsulfoxide (DMSO) control for 4 hours. NSC-34 cell lysates, ntg 
SOD1
G93A
 and caspase-6 
-/-
 lumbar spinal cord homogenates (controls) were probed with 
antibodies that recognize pro caspase-6 (36 kDa), cleaved caspase-6 (15 kDa), cleaved 
caspase-3 (19 kDa), and α-tubulin loading control (55 kDa). Pro caspase-6 was detected in all 
samples except caspase-6
-/-
. Cleaved caspase-6 could not be detected in any samples. 
Expected 
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Cleaved caspase-3 was detected in STS-treated NSC-34 lysates indicating apoptosis was 
induced by STS treatment.                                 
3.2.3 Pro caspase-6 protein levels during disease progression in the SOD1
G93A 
mouse 
model of ALS 
ALS is a progressive degenerative disease, and is usually identified firstly in the lower limbs 
as a loss of muscular function. Molecular mechanisms of apoptosis may be involved in 
motorneuron death produced by mutations in the SOD1 gene (Guegan et al. 2001). 
Activation of other caspases have been located in the spinal cord of tg SOD1
G93A
 mice, 
including caspase-9 and caspase-3 (Guegan et al. 2001). It has been observed via Western 
blot that activation of caspase-3 and caspase-7 occur during later stages of disease 
progression in SOD1
G93A
 mice (Pasinelli et al. 2000; Vuckosavc et al. 2000), therefore we 
hypothesized that caspase-6 expression levels or activation may be altered in SOD1
G93A
 mice. 
To identify the role of caspase-6 in an ALS mouse model we measured pro caspase-6 levels 
in tg and ntg SOD1
G93A
 lumbar spinal cord homogenates throughout disease progression. 
Western blots were probed with an antibody that recognizes pro caspase-6 (36 kDa) and 
either β-actin or α-tubulin was used as a loading control (55 kDa). The caspase-6 specific 
band in SOD1
G93A
 lumbar spinal cord samples was identified by the absence of a band in the 
caspase-6
-/-
 lane. Non-specific bands were also present (indicated by nsp) and cleaved 
caspase-6 could not be detected. Due to limited starting material and minimizing animal 
numbers, repeats of this experiment were not performed. 
Although pro caspase-6 was detected as a band of 36 kDa in all samples, there were no 
significant changes in expression in SOD1
G93A
 spinal cord at pnd 70 (Figure 3.4), pnd 120 
(Figure 3.5), or pnd endstage (Figure 3.6). Cleaved caspase-6 could not be detected at any of 
these timepoints, which is similar to the findings in the STS-treated NSC-34 cells.  
It should be noted that at endstage, densitometric analysis of the pro caspase-6 signal 
normalised to the α-tubulin loading control, revealed that there were increased levels of pro 
caspase-6 in the tg lumbar spinal cord samples (n=4) compared to non-tg (n=4) littermates, 
however this was not statistically significant (Figure 3.6). Due to limited starting material and 
minimizing animal numbers, repeats of this experiment were not performed, therefore data 
analysis was completed using one Western blot for each timepoint. 
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A) 
 
               
B) 
                                     
 
Figure 3.4: Caspase-6 protein expression in PND 70 lumbar spinal cord 
 
A) Representative western blot of ntg and transgenic (tg) SOD1
G93A
 lumbar spinal cords 
homogenized in RIPA buffer at pnd 70. Samples were probed with antibodies that recognize 
pro caspase-6 (36 kDa), cleaved caspase-6 (15 kDa), and α-tubulin loading control (55 kDa). 
<nsp= non-specific band (B) Densitometry quantification of pro caspase-6 expression level at 
pnd 70 in the SOD1
G93A
 colony relative to β-actin showed no significant differences in 
expression. Cleaved caspase-6 could not be detected in any samples. Analysis was performed 
on n=3 tg samples and n=6 ntg samples. Limited starting material and keeping animal 
numbers to a minimum prevented repeats of this experiment (n=1).  Error bars represent the 
SEM. 
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A) 
                
                                          
B) 
                                
Figure 3.5: Caspase-6 protein expression in PND 120 lumbar spinal cord 
 
A) Representative western blot of ntg and tg SOD1
G93A
 lumbar spinal cords homogenized in 
RIPA buffer at PND 120. Samples were probed with antibodies that recognize pro caspase-6 
(36 kDa), cleaved caspase-6 (15 kDa), and α-tubulin loading control (55 kDa). <nsp= non-
specific band. (B) Densitometric quantification of caspase-6 expression levels at pnd 120 in 
the SOD1
G93A
 colony relative to β-actin showed there was no significant difference in 
expression between tg and ntg animals. Cleaved caspase-6 could not be detected in any 
Expected  
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samples. Analysis was performed on n=4 tg samples and n=4 ntg samples. Limited starting 
material and keeping animal numbers to a minimum prevented repeats of this experiment 
(n=1). Error bars represent the SEM. 
A) 
           
B) 
                                    
 
Figure 3.6: Caspase-6 protein expression in PND endstage lumbar spinal cord 
 
(A) Representative western blot of ntg and tg SOD1
G93A
 lumbar spinal cords homogenized in 
RIPA buffer at pnd endstage (which occurs around pnd 150-160). Samples were probed with 
antibodies that recognize pro caspase-6 (36 kDa), cleaved caspase-6 (15 kDa), and α-tubulin 
loading control (55 kDa). <nsp= non-specific band. (B) Densitometric quantification of 
caspase-6 expression levels at pnd endstage in the SOD1
G93A
 colony relative to β-actin 
showed that there was increased expression in tg samples but this was not significantly 
   < nsp 
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different. Cleaved caspase-6 could not be detected in any samples. Blot represents 
experiments performed on n=4 ntg samples and n=4 tg samples. Limited starting material and 
keeping animal numbers to a minimum prevented repeats of this experiment (n=1). <nsp= 
non-specific band Error bars represent the SEM.   
3.3 Summary 
We utilized quantitative PCR (qPCR) to determine pro caspase-6 mRNA in nervous tissue 
from neocortex as well as ntg SOD1
G93A
; caspase-6
-/-
 gastrocnemius muscle (pnd 35), ntg 
SOD1
G93A
; caspase-6
+/+
 gastrocnemius muscle (pnd 35), and compared this with purified 
primary motorneurons, microglia-enriched and astrocyte-enriched cultures from primary E12 
spinal cord tissue. No significant differences in caspase-6 mRNA expression were detected in 
the sample types examined compared to nervous tissue.  
We decided to investigate if caspase-6 protein levels were altered in a transgenic mouse 
model of ALS. We identified pro caspase-6 in the lumbar spinal cord of both tg and ntg 
SOD1
G93A
 mice. Having observed the presence of pro caspase-6 in our mouse model, we 
wanted to determine if caspase-6 has a role in disease pathology. We found that pro caspase-6 
showed a tendency towards an increase with the progression of ALS, yet this was is not at 
statistically significant levels. Successful detection of cleaved caspase-6 expression via 
Western blot in SOD1
G93A
 lumbar spinal cord was not achievable due to poor primary 
antibodies; therefore we cannot exclude the possibility of active caspase-6 across disease 
progression. While pro caspase-6 is not significantly upregulated in the lumbar spinal cord, it 
still may play a role in apoptosis mediated degeneration at earlier stages of the disease in 
another region. It has been hypothesized that caspase-6 may have a role in the degeneration in 
skeletal muscle occurs prior to the onset of motorneuron degeneration in the spinal cord 
(Graham et al. 2006). Although there is increasing information regarding ALS disease 
pathology every year, many efforts are focused on understanding motorneuron degeneration 
in the spinal cord. We were interested in discovering if caspase-6 played a larger pre-
symptomatic role in an area that is only beginning to gain attention, in skeletal muscle 
(Chapter 4). 
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Chapter 4: The role of caspase-6 during motorneuron degeneration  
4 .1 Introduction 
Due to beneficial evidence involving targeted deletion of caspase-6 in HD and AD (Graham 
et al. 2010; Milnerwood et al. 2010; Galvan, V. et al. 2006; Nguyen, T.V. et al. 2008),  we 
were interested in determining any implications of a caspase-6 deficiency on ALS disease 
progression and survival by utilizing the SOD1
G93A
  mouse. 
In this chapter, we determined whether caspase-6 deficient mice display any change in body 
weight or motor function when compared to ntg SOD1
G93A
 mice. We also examined any 
differences in motor endplate morphology of caspase-6
-/-
 mice compared to wildtype 
SOD1
G93A
 mice. To define the role of caspase-6 deletion in the SOD1
G93A
 mouse model of 
ALS, we cross-bred caspase-6
-/-
 mice with tg SOD1
G93A 
mice to generate a new mouse strain. 
Motor function tests and lifespan analysis were carried out in all of the genotypes generated. 
Finally, we determined if any differences were present in skeletal muscle weight and 
morphology in the SOD1
G93A
; caspase-6 mice. 
4.2 Results 
4.2.1 Characterisation of caspase-6 deficient mice  
To gain a better understanding of caspase-6 deficiency in vivo, motor performance, body 
weight, and motor endplate morphology were characterized. Non-transgenic SOD1; caspase-
6 
-/-
 mice were assessed by Rotarod test and the body weights were recorded and compared to 
ntg SOD1
G93A
 mice. The Rotarod test was chosen due its sensitivity for indicating disease 
onset and progression in the SOD1
G93A
 mouse model (Knippenberg, Thau et al. 2010). 
Rotarod analysis showed no significant difference in performance between caspase-6 
deficient and ntg SOD1
G93A
 mice (Figure 4.1B). Body weight was recorded prior to Rotarod 
testing using a standard weighing scale. There were no significant changes in body weight 
between ntg SOD1; caspase-6 
-/- 
and ntg SOD1
G93A
 mice (Figure 4.1A). Non-transgenic 
littermates are culled at the same time as the tg mice for direct comparison, even though they 
would survive much longer.  Because ntg mice are culled at the same time as tg mice and the 
same pattern is seen (Figure 4.10) where tg SOD1
G93A
; caspase-6
-/-
 mice die earlier than                                               
tg SOD1
G93A
; caspase-6
 +/+
mice. It should also be noted that all ntg SOD1
G93A
; caspase-6
-/-
 
male mice were culled at pnd 165, the same time as tg SOD1
G93A
; caspase-6
-/-
, (data shown in 
Figure 4.10) and therefore female weight averages, which are naturally less, demonstrate a 
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decrease at this time point (Figure 4.1A). In addition, separate analysis of male and female 
data did not show any differences in body weight (data not shown). Initial characterization of 
caspase-6 deficient mice was necessary for the continuation of additional motor function tests 
(chapter 4.2.3) in the SOD1
G93A
; caspase-6
-/-
 cross breeding. 
A) 
 
 
B) 
  
 
Figure 4.1: Motor function and body weight are not affected in non-transgenic SOD1
 
G93A
 mice deficient for caspase-6 
A) Weight analysis is used as an indication of disease onset and progression. Male and 
female body weight measurement commenced at pnd 63 until the loss of righting reflex 
which occurs at approximately pnd 160 in tg SOD1
G93A
 mice. There was no significant 
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difference between ntg SOD1
G93A
; caspase-6
 +/+ 
and ntg SOD1
G93A
; caspase-6
 -/-
 mice. 
Transgenic mice are culled at the same time and therefore show the same pattern (Figure 
4.10) where tg SOD1
G93A
; caspase-6
-/-
 mice die earlier than tg SOD1
G93A
; caspase-6
 
+/+
mice. Analysis of male and female data separately showed no significant differences 
between male and female mice (data not shown). B) The Rotarod test provides an 
analysis of limb strength and loss of function is used as a measurement of disease onset 
and progression. The Rotarod test commenced at pnd 63 until the loss of righting reflex 
at approximately pnd 160. Data analysis showed no significant difference between ntg 
SOD1
G93A
; caspase-6
 +/+
 and ntg SOD1
G93A
; caspase-6
 -/-
. There were no significant 
differences seen when males and females were analysed separately (data not shown). 
Data analysis was completed with n= ≥5 per sex-matched group. Statistical tests used 
were-ANOVA followed by a post hoc Tukey test. Error bars represent the SEM. 
 
Next, we wanted to determine if motor endplates from hindlimb skeletal muscle showed any 
morphological changes in caspase-6 deficient mice compared to ntg SOD1
G93A 
mice. 
Gastrocnemius muscle was dissected from pnd 90 mice and sectioned at 30µm. Muscle 
sections from ntg SOD1
G93A
 mice and caspase-6
-/-
 mice were stained with α-bungarotoxin (a-
BTX) which binds with high affinity to the α-subunit of the nicotinic acetylcholine receptor 
(AChR) of neuromuscular junctions to identify motor endplates (Figure 4.2A). Analysis of 
motor endplates from caspase-6
-/-
 gastrocnemius muscle showed no difference in 
morphology compared to ntg SOD1
G93A
.  
 
 
 
 
 
 
 
 
 
 
 
  
67 
 
A) 
 
 
Figure 4.2: Neuromuscular endplates show no difference in morphology in ntg 
SOD1
G93A
 mice compared to caspase-6
-/-
 mice 
A) Gastrocnemius muscle was dissected from pnd 90 mice and sectioned at 30µm. Muscle 
sections from ntg SOD1
G93A
 mice and caspase-6
-/-
 mice were stained with α-bungarotoxin (a-
BTX) to identify motor endplates. Analysis of motor endplates from ntg SOD1
G93A
 mice 
compared to caspase-6
-/-
 mice showed no differences in morphology. Preliminary data 
images are of n=1 per group. Scale bar=10µm 
 
4.2.2 Generation of the SOD1
G93A
; caspase-6 
-/-
 colony 
To further elucidate the role of caspase-6 during ALS disease progression, we developed a 
cross-breeding program to produce a SOD1
G93A
 mouse colony deficient for caspase-6 (Figure 
4.3). SOD1
G93A 
are commercially available from the Jackson Laboratories, strain name 
B6.Cg-Tg (SOD1*G93A) 1Gur/J. Caspase-6 deficient mice are also available from the 
Jackson Laboratories, strain name B6.129S6-Casp6
tmlFlv
/J. Mice were weaned at 4 weeks and 
genotype was confirmed by tail snip PCR for SOD1
G93A
 (Figure 4.4A) and caspase-6 (Figure 
4.4B) mice. Breeding commenced at 6 weeks when the mice reached sexual maturity (Leitner 
et al. 2009). Breeding paradigms were adapted to produce the genotypes of interest (Figure 
4.3). Transgenic SOD1
G93A
 females are inefficient breeders (Leitner et al. 2009), therefore tg 
SOD1
G93A
 males were crossed with caspase-6
-/-
 females to generate tg and ntg SOD1
G93A
; 
caspase-6
+/-
 mice. The resulting tg SOD1
G93A
; caspase-6
+/-
 males were crossed with caspase-
6
-/-
 females to generate male and female tg SOD1
G93A
; caspase-6
-/-
 and ntg SOD1
G93A
 
caspase-6
-/-
 mice necessary for this study.  Due to low ntg SOD1
G93A
; caspase-6
+/+
 numbers, 
ntg SOD1
G93A
 mice from the SOD1
G93A
 colony were age, and sex matched and utilized as a 
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control. SOD1
G93A
 mice with a caspase-6 deficiency were produced at expected Mendelian 
frequencies and do not display any obvious alteration in phenotype prior to onset of ALS 
symptoms. In addition deletion of caspase-6 does not alter the expression of human SOD1 
levels (Figure 4.5A). 
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 A) 
             SOD1
G93A
 mice: 
              tg   X    ntg       yields both tg and ntg males and females 
             *SOD1
G93A
   tg = infertile 
 
           SOD1
G93A
/CASP6 mice: 
         tg SOD1
G93A
 / CASP6 +/+    X       ntg SOD1
G93A
 / CASP6  -/-  
             
                 Resulting genotypes:  tg SOD1
G93A
 / CASP6 +/- 
                                                      ntg SOD1
G93A
 / CASP6 +/- 
 
     tg SOD1
G93A
 / CASP6 +/-       X         ntg SOD1
G93A
 / CASP6 -/- 
 
                Resulting genotypes:  tg SOD1
G93A
 / CASP6 +/- 
                                                     ntg SOD1
G93A
 / CASP6 +/- 
                                                      tg SOD1
G93A
 / CASP6 -/- 
                                                      ntg SOD1
G93A
 / CASP6 -/- 
 
Figure 4.3:  Generation of the SOD1
G93A
 Caspase-6 -/- colony 
A) SOD1
G93A
 and caspase-6 
-/-
 mice were cross bred to generate a SOD1
G93A
; caspase-6 
-/-
 
colony. Transgenic SOD1
G93A
 males were crossed with caspase-6
-/-
 females to generate tg 
SOD1
G93A
; caspase-6
-/-
 mice for motor function and lifespan analysis. 
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A) 
 
 
 
 
B) 
 
 
 
Figure 4.4:  SOD1
G93A 
and caspase-6 genotypes were determined by polymerase chain 
reaction (PCR)  
A) Tail snip DNA genotyping was carried out to identify genes of interest. A 2 millimetre 
(mm) section of tail was taken from each mouse and DNA was extracted from tail snips using 
a High Pure PCR Template Preparation Kit. Samples were run in the thermal cycler with an 
annealing program that was pre-set with primers specific to the gene of interest. Samples 
were then run on a 2% agarose gel and analysed. Non-transgenic SOD1
 G93A
 was identified as 
a band at 324 bp and tg SOD1
 G93A
 was identified by the presence of a band at 236 bp. B) 
SOD1
G93A
 and caspase-6 
-/-
 mice were cross bred to generate a SOD1
G93A
;caspase-6
-/-
 colony. 
Caspase-6 (+/+, +/-, -/-) and SOD1 (tg and ntg) expression were identified in each litter 
produced. Caspase-6 
+/+
 was identified by a band at a 620 bp band, and caspase-6 
-/-
 was 
identified at 340 bp whereas heterozygouse caspase-6 
+/-
 had both bands 620 bp and 340 bp.  
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A) 
      
      
B) 
                                               
Figure 4.5: Caspase-6 deficiency in SOD1
G93A
 mice did not alter the expression of 
human SOD1
G93A
 expression levels 
A)  Transgenic and ntg SOD1
G93A
; caspase-6 
-/-
 , tg and ntg SOD1
G93A
; caspase-6
+/+
 and 
caspase-6 
-/-
 (control) lumbar spinal cord homogenates were probed with antibodies that 
recognize pro caspase-6 (36 kDa), hSOD1 (19 kDa), and β-actin (55 kDa) loading control. 
Caspase-6 deficiency did not alter the expression of human SOD1 in tg SOD1
G93A
 mice. B) 
Densitometric quantification of hSOD1 expression in tg SOD1
G93A
; caspase-6 
-/-
 and tg 
SOD1
G93A
; caspase-6
+/+
 showed no significant differences in hSOD1 expression levels 
relative to β-actin. Blot experiment was performed with n=3 mice per genotype. Error bars 
represented as SEM. Statistical analysis was performed using an Independent T-test. 
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4.2.3 Effect of caspase-6
-/-
 deletion on disease progression and motor function in 
SOD1
G93A 
mice 
The loss of motor function is a common phenotypic indicator of ALS disease onset and 
progression in transgenic SOD1
G93A 
mice. The onset of symptoms can be seen at pnd 90 with 
a progressive reduction in function until pnd endstage, usually 70 days after symptom onset. 
Endstage is determined when the ability for the mouse to right itself can no longer be 
achieved after 30 seconds on either side (Ludolph et al. 2010). The first physical symptoms 
of the SOD1
G93A
 mouse model were identified by Gurney and Pu et al, by observing hind leg 
extension, grooming habits, and weight loss (Gurney, Pu et al. 1994). Several methods of 
analysing motor function performance have been developed including Rotarod test, grip 
strength meter, PaGE test (Weydt et al. 2003), and stride length measurements (Gurney, Pu et 
al. 1994). These relevant methods for testing motor function are non-invasive and widely 
accepted for analysing the SOD1
G93A
 mouse model (Brooks and Dunnett, 2009). These tests 
have been used in several studies associated with evaluating pre-clinical therapies in 
SOD1
G93A
 mice (Ludolph, Bendotti et al. 2007; Scott, Kranz et al. 2008; Brooks and Dunnett 
2009; Ludolph, Bendotti et al. 2010). Each group, ranging from 4-8 mice per group, was sex, 
age, and litter matched prior to motor function analysis based on the accepted guidelines for 
ALS animal studies (Ludolph, et al., 2010). The tg and ntg SOD1
G93A
; caspase-6
+/+
 control 
mice were sex, age, and litter matched separately. Motor function analysis commenced at pnd 
63 following a training period of 10 days. All motor function testing was recorded with tests 
completed in the same order, twice weekly. 
 
The Rotarod test provides an analysis of limb strength and coordination, and loss of function 
is used as a measurement of disease onset and progression. Rotarod
 
analysis shows a 
significant decrease in performance in tg SOD1
G93A
; caspase
-/-
 mice from pnd 137 (p≤0.05) 
to pnd 159 (p≤0.001) compared to tg SOD1G93A; caspase+/+ mice (Figure 4.6A). Male and 
female Rotarod performance was also analysed separately. Male Rotarod performance 
showed a significant decrease in performance in tg SOD1
G93A
; caspase
-/-
 mice at pnd 145 
(p≤0.01) compared to tg SOD1G93A; caspase+/+ mice but no significance was seen during 
later timepoints (4.6B). Females demonstrated a decrease in performance in tg SOD1
G93A
; 
caspase
-/-
 mice from pnd 135 (p≤0.001) to pnd 159 (p≤0.050) compared to tg SOD1G93A; 
caspase
+/+
 mice (Figure 4.6C).  
 
  
73 
 
The PaGE test is used to measure the strength of the forelimbs and hindlimbs. Loss of 
function in the limbs is an indication of disease onset and progression. The PaGE test requires 
the mouse to use both fore and hindlimbs to hang upside down on a mesh metal grate for as 
long as possible or a maximum of 60 seconds.  PaGE ability was reduced during early disease 
progression at pnd 95 in tg SOD1
G93A
; caspase-6
-/-
 in contrast to the onset of forelimb 
symptoms in tg SOD1
G93A
; caspase
+/+
 at pnd 112 (Figure 4.7). Transgenic SOD1
G93A
; 
caspase
+/+
 mice performed better in the PaGE test compared to their caspase
-/-
 littermates 
from pnd 95 (p≤0.010) to pnd 112 (p≤0.001), but showed no significant differences from pnd 
112 to endstage. Following the PaGE test, the grip strength test was used to measure forelimb 
strength and the force applied (g) to resist the involuntary backward movement when a mouse 
was pulled by its tail. Grip strength was performed twice weekly and the average of each 
reading was analysed across disease progression. Transgenic SOD1
G93A
; caspase-6
-/-
 mice 
showed a significant decrease in PaGE performance when compared to tg SOD1
G93A
 mice 
during disease onset (pnd 90) (p≤0.010) to late-stage of the disease (pnd 120) (p≤0.010) but 
no other significant differences were recorded (Figure 4.8A). Male and female grip strength 
analysis did not yield a significant difference between tg SOD1
G93A
; caspase-6
-/-
   and tg 
SOD1
G93A
; caspase
+/+
 mice (Figure 4.8B/Figure 4.8C). 
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Figure 4.6: Caspase-6 deficiency does not protect limb function across disease 
progression in SOD1
G93A
 mice 
A) Rotarod performance measures both forelimb and hind limb function. Rotarod
 
testing 
commenced at pnd 63 following a training period until the loss or right reflex at 
approximately pnd 160. Rotarod
 
analysis depicts a significant decrease in performance in tg 
SOD1
G93A
; caspase
-/-
 mice compared to tg SOD1
G93A
; caspase
+/+
 mice from pnd 137 
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(p≤0.050) to pnd 159 (p≤0.001) B) Male tg SOD1G93A ; caspase-6 -/- mice Rotarod(R)  
performance showed no overtly significant results but demonstrated a decrease in 
performance at pnd 145 when compared to male tg SOD1
G93A
  mice.  C) Female performance 
showed a decrease from tg SOD1
G93A
; caspase
-/-
 mice compared to tg SOD1
G93A
; caspase
+/+
 
mice from pnd 135 (p≤0.05) to pnd 159 (p≤0.05). ANOVA (post-hoc, Tukey) was used to 
assess statistical significance. Data are mean ± SEM, n= 4-6 mice per sex-matched treatment 
group (* p≤0.05, ** p≤0.01, *** p≤0.001) 
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A) 
 
 
                                                                 
Figure 4.7 Caspase-6 deficiency does not protect muscle endurance across ALS disease 
progression in SOD1
G93A
 mice 
A) Mice were suspended on a mesh cage for up to a 60 second latency to fall. Mice were 
assessed twice a week and the two latency scores were averaged at the end of each week. 
Motor function testing commenced at pnd 63 following a training period until the loss or 
  
77 
 
righting reflex at approximately pnd 160. Transgenic SOD1
G93A
; caspase-6
-/-
 mice showed a 
decrease in PaGE  performance when compared to tg SOD1
G93A
  mice during disease onset  
at pnd 90 until pnd 120 (p≤0.05) but no other significant differences were recorded. B) Male 
tg SOD1
G93A
; caspase-6
-/-
 mice demonstrated an earlier onset of loss of function than females 
and demonstrated a decrease in performance at disease onset (pnd 90) until late stage (pnd 
120) compared to tg SOD1
G93A
; caspase-6
+/+
 mice. C) Female PaGE analysis showed no 
significance. ANOVA (post-hoc, Tukey) was used to assess statistical significance. Data are 
mean ± SEM, n= 4-6 mice per sex-matched treatment group (* p≤0.05, ** p≤0.01, *** 
p≤0.001) 
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A) 
 
 
                                                                  
Figure 4.8: Caspase-6 deficiency decreases grip strength endurance in SOD1
G93A
 mice  
A) Grip strength meter assessment was used to determine forelimb strength. Mice were 
dragged across a trapeze which they instinctively grasped. The mice were pulled back and the 
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force of the resistance was recorded. Grip strength was performed twice weekly and the 
average of each reading was analysed across disease progression. Motor function testing 
commenced at pnd 63 following a training period until the loss or right reflex at 
approximately pnd 160. Transgenic SOD1
G93A
; caspase-6
-/-
 mice showed a decrease in PaGE 
performance when compared to tg SOD1
G93A
; caspase-6
+/+
 mice during disease onset (pnd 
90) to late-stage of the disease (pnd 120) but no other significant differences were recorded. 
B) Male grip strength analysis showed significance at pnd 97 (p=0.05) to pnd 112 (p=0.05) 
for tg SOD1
G93A
; caspase-6
-/-
 compared to tg SOD1
G93A
; caspase-6
+/+
 mice. C) Female grip 
strength analysis showed no significance for tg SOD1
G93A
; caspase-6
-/-
 compared to tg 
SOD1
G93A
; caspase-6
+/+
 mice. ANOVA (post-hoc, Tukey) was used to assess statistical 
significance. Data are mean ± SEM, n= 4-6 mice per sex-matched treatment group (* p≤0.05, 
** p≤0.01, *** p≤0.001) 
 
 
As previously described, stride lengths were measured on two consecutive left-to-left and 
right-to-right footprints and recorded twice a week. Transgenic SOD1
G93A
; caspase-6
 -/-
 mice 
showed a significant decrease in stride length during late-stage of the disease at pnd 140 
(p≤0.001) to endstage of the disease (p≤0.05) when compared to tg SOD1G93A; caspase-6+/+ 
(Figure 4.9A). Male stride length was analysed with one significant result demonstrated by a 
decrease in stride length performance at pnd 160 for tg SOD1
G93A
; caspase-6
 -/-
 mice 
compared to tg SOD1
G93A
; caspase-6
 +/+
 mice (Figure 4.9B). Female stride length showed 
significance from pnd 140 (p≤0.01) to pnd 147 (p≤0.001) and at endstage of the disease (pnd 
160) (p≤0.01) when compared to tg SOD1G93A; caspase-6 +/+ (Figure 4.9C). Weight was also 
measured twice weekly and recorded for all genotypes. A decrease in body weight along with 
decreasing motor performance is an indication of disease progression in SOD1
G93A 
mice. 
Transgenic SOD1
G93A
; caspase
-/-
 mice maintained their weight compared to tg SOD1
G93A
; 
caspase
+/+
 controls from pnd 63 to end stage (Figure 4.10A). Male and female analysis also 
showed no significant results for body weight (4.10B/4.10C). These in vivo results suggest 
that caspase-6 deficiency does not protect limb function, endurance, and motility across 
disease progression in SOD1
G93A
 mice and has no effect on body weight. 
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A) 
 
 
                                                                   
Figure 4.9: Caspase-6 deficiency decreases hind limb motility in SOD1
G93A
 mice  
A) The hind limbs of each mouse were painted with non-toxic paint and the mouse was 
trained to walk in a straight line along a sheet of paper. Two consecutive paw prints on the 
left and right foot were measured in millimetres (mm) and averaged for analysis. Stride 
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length measurement was performed weekly and recorded. Motor function testing commenced 
at pnd 90 following a training period until the loss or right reflex at approximately pnd 160. 
Transgenic SOD1
G93A
; caspase-6
 -/-
 mice showed a significant decrease in stride length when 
compared to tg SOD1
G93A
; caspase-6
 +/+
   mice during late stages of the disease (pnd 140) to 
endstage of the disease (pnd 160). B) Male stride length was analysed but no overtly 
significant results were found. C). Female stride length showed significance from pnd 140 
(p≤0.01) to late-stage of the disease (pnd 160) when compared to tg SOD1G93A; caspase-6 +/+. 
ANOVA (post-hoc, Tukey) was used to assess statistical significance. n= 4-6 mice per sex-
matched treatment group (* p≤0.05, ** p≤0.01, *** p≤0.001) Data are mean ± SEM. 
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A)  
 
 
                                                                    
Figure 4.10: Caspase-6 deficiency does not affect body weight across disease progression 
in SOD1
G93A 
mice  
A) Body weight was measured for each mouse, twice weekly with the average weekly 
bodyweight recorded. Weight was measured on a laboratory scale and recorded in grams (g). 
Body weight measurement commenced at pnd 63 until the loss or right reflex at 
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approximately pnd 160. No significant difference was detected between tg SOD1
G93A
; 
caspase-6
 -/-
 and tg SOD1
G93A
; caspase-6
+/+
   mice, however the caspase-6
 -/-
 mice 
consistently showed lower body weight throughout disease progression.  B) Neither male nor 
female body weight analysis showed significant difference. ANOVA (post-hoc, Tukey) was 
used to assess statistical significance. n= 4-6 mice per sex-matched treatment group. Data are 
mean ± SEM 
 
4.2.4 Effect of Caspase-6 
-/-
 deletion on lifespan and survival in SOD1
G93A 
mice 
To further elucidate the role of caspase-6, we recorded the lifespan of SOD1
G93A
; caspase-6
 -/-
 
mice to examine the effect of caspase-6 deletion during disease progression. As previously 
described, mice were age, sex, and litter matched according to guidelines for pre-clinical ALS 
animal research (Ludolph, Bendotti et al., 2010). Survival was plotted on a Kaplan Meier 
curve. Non-parametric analysis revealed that genetic deletion of caspase-6 did not increase 
survival in tg SOD1
G93A
; caspase-6
-/-
 mice compared to tg SOD1
G93A
 ; caspase-6
+/+
 
littermates, in fact it significantly decreased survival. Kaplan-Meier analysis of SOD1
G93A
; 
caspase-6
-/-
 colony showed a significant decrease in lifespan between tg SOD1
G93A
; caspase-
6
+/+
 (167 ± 2 day) and tg SOD1
G93A
; caspase-6
-/-
 (161 ± 1) mice (p=0.009) (Figure 4.11).   
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A) 
 
 
Figure 4.11: Decreased lifespan in the SOD1
G93A
; caspase-6
-/- 
colony  
 
(A) Kaplan Meier analysis representing percentage of survival between SOD1
G93A
; caspase-
6
-/-
 and SOD1
G93A
; caspase-6 
+/+
 littermates. Endstage was assessed through an inability for 
any one mouse to right itself within 30 sec when placed on either side. Endstage mice were 
culled by intra-cardial perfusion. Lifespan was calculated for each mouse from date of birth 
up to/and including the day they were culled. Transgenic SOD1
G93A
; caspase-6 
+/+
 (167 ± 1 
day) mice survived longer than tg SOD1
G93A
; caspase-6
-/-
 (161 ± 1). Data represent n= 17 
SOD1
G93A
; caspase-6 
-/-
 (n=7 males and n=10 females) and n=14 wildtype mice (n=5 males 
and n=9 females). No significant differences were found when male versus female lifespan 
was analysed. Kaplan-Meier analysis was assessed using SPSS statistical analysis software. 
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A) 
 
        
Figure 4.12: Average lifespan for tg mice from the SOD1
G93A
 Caspase-6 
-/- 
colony  
 
A) Lifespan was calculated for each mouse from date of birth up to/and including the day 
they were culled. Average lifespan was compared and statistical analysis showed that tg 
SOD1
G93A
; caspase-6 
+/+
 (167 ± 2 day) mice survived longer than tg SOD1
G93A
; caspase-6
-/-
 
(161 ± 1 day) (p=0.009) n= 4-6 mice per sex-matched treatment group (* p≤0.05, ** p≤0.01, 
*** p≤0.001) Data are mean ± SEM 
 
 
These in vivo results described here suggest that caspase-6 deficiency does not protect limb 
function, endurance, and motility across disease progression in SOD1
G93A
 mice and has no 
effect on body weight. In contrast to what we expected, caspase-6 deletion appears to make 
ALS disease progression in the SOD1
G93A
 mouse model significantly worse. 
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4.2.5 Characterization of skeletal muscle in the SOD1
G93A
; caspase-6 
-/-
 colony 
In ALS, it has been proposed that abnormalities within skeletal muscle participate in 
triggering motor neuron degeneration and that alterations in different cell types may work 
together to exacerbate the disease (Pansarasa et al. 2014). A recent study completed by Wong 
and Martin (2010) showed that tg SOD1
G93A
 mice with site specific expression of SOD1
 
in 
skeletal muscle developed severe pathology involving oxidative damage, protein nitration, 
myoﬁber cell death and NMJ abnormalities (Wong and Martin, 2010). Another study utilized 
overexpressed mitochondria-targeted photoactivatable fluorescent proteins to identify 
abnormal mitochondrial dynamics in skeletal muscle of SOD1
G93A
 mice which occurred 
before disease onset (Luo et al. 2013). The primary location for motor dysfunction, either 
within motor neurons, within the motor axon, or at the level of the NMJ, is a question that is 
still unanswered. It has been hypothesized that the “dying-back” phenomena may be 
implicated in ALS disease pathology, where the distal axon degenerates before neuronal 
degeneration (Fischer et al. 2004).  It has been suggested that this phenomena occurs in 
skeletal muscle (Fischer et al. 2004) and has become an area of interest in ALS disease 
research. Our group decided to look for evidence of muscular atrophy by investigating 
changes in weight and width of skeletal muscle in SOD1
G93A
;caspase-6
-/- 
colony compared to 
SOD1
G93A
 mice. 
Gastrocnemius muscles from ntg SOD1
G93A
; caspase-6
+/+
, tg SOD1
G93A
; caspase-6
+/+ 
, ntg 
SOD1
G93A
; caspase-6
-/- 
, and tg SOD1
G93A
; caspase-6
-/-  
were dissected and photographed to 
compare the degree of muscular atrophy. The width of each muscle was measured and 
compared. A significant difference was observed for tg SOD1
G93A
; caspase-6
-/- 
(p≤0.001) 
muscle width compared to ntg SOD1
G93A
; caspase-6
-/- 
samples (Figure 4.13Ad). Muscle 
width in tg SOD1
G93A
; caspase-6
+/+ 
(p≤0.001) compared to ntg SOD1G93A; caspase-6+/+ 
samples also showed significant difference. No significance was found between tg 
SOD1
G93A
; caspase-6
+/+
 and tg SOD1
G93A
; caspase-6
-/- 
groups, suggesting that caspase-6 
deficiency does not affect muscle degeneration when measured at pnd endstage.  
Gastrocnemius muscles were also weighed. Although tg SOD1
G93A
; caspase-6
-/-  
muscle 
showed a decreased weight (p≤0.001) in comparison to ntg SOD1G93A; caspase-6-/-  muscle, tg 
SOD1
G93A
; caspase-6
-/- 
 muscle weight did not yield significance when compared to tg 
SOD1
G93A
; caspase-6
+/+ 
muscle (Figure 4.13B). This data suggests that deletion of caspase-6 
does not affect directly affect muscular atrophy in SOD1
G93A 
mice.  
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A) 
 
B) 
 
Figure 4.13: Characterization of gastrocnemius muscle at PND endstage in the 
SOD1
G93A
 Caspase-6 
-/-
 colony shows a decrease in weight and morphology 
A) Gastrocnemius muscles from ntg SOD1
G93A
; caspase-6
+/+
, tg SOD1
G93A
; caspase-6
+/+ 
, 
ntg SOD1
G93A
; caspase-6
-/- 
, tg SOD1
G93A
;caspase-6
-/-  
were dissected and photographed to 
compare the degree of muscular atrophy. Images were taken with muscle samples in the order 
of: tg SOD1
G93A
; caspase-6
+/+ 
(n=3), tg SOD1
G93A
; caspase-6
+/+ 
(n=3), ntg SOD1
G93A
; 
 
 
*** 
*** 
*** 
*** 
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caspase-6
+/+ 
(n=3), and tg SOD1
G93A
; caspase-6
-/- 
(n=3). B) Gastrocnemius muscles were 
weighed and averaged. Significance was detected between tg SOD1
G93A
; caspase-6
 -/-
 and ntg 
SOD1
G93A
; caspase-6
+/+ 
muscle. Transgenic SOD1
G93A
; caspase-6
-/- 
muscle weight did not 
yield significance when compared to tg SOD1
G93A
; caspase-6
+/+ 
muscle. Data were analysed 
using one-way ANOVA. Data are mean ± SEM 
 
4.3 Summary 
Apoptosis has been implicated in ALS disease progression in humans and SOD1 mouse 
models (Portera-Cailiau et al. 1997; Sathasivam et al. 2001; Ghavami et al. 2014). Several 
groups have shown that deletion of caspase-6 in vitro may be beneficial in neurodegeneration 
(Nikolaev et al. 2009; Vohra et al. 2010), initiating an interest in caspase-6 as a therapeutic 
target for ALS. Uribe et al demonstrated through in vitro experiments that deletion of 
caspase-6 in neurons promotes protection against excitotoxicity, nerve growth factor 
deprivation and myelin-induced axonal degeneration (Uribe et al. 2012).  We wanted to 
determine if deletion of caspase-6 would be beneficial in vivo, therefore we generated a 
cross-breeding program to include caspase-6 deficiency in an ALS mouse model. Prior to the 
generation of the SOD1
G93A
; caspase-6 colony, we showed that the phenotype, Rotarod 
performance, and body weight was not altered with the deletion of caspase-6 compared to 
wildtype. We also investigated whether motor endplate morphology was altered in caspase-6 
deficient mice compared to ntg SOD1
G93A
 mice (Figure 4.2). Our findings showed no obvious 
signs of variation. To elucidate the role of caspase-6 in ALS, we generated a cross breeding 
to include: tg SOD1
G93A
; caspase-6
-/-
, tg SOD1
G93A
; caspase-6
+/+
, ntg SOD1
G93A
; caspase-6
-/-
, tg SOD1
G93A
; caspase-6
-/- 
(Figure
 
4.3).  
To investigate the implications of a caspase-6 deficiency in vivo, we monitored and recorded 
motor function performance and lifespan from pnd 63 to endstage. Our results showed that 
caspase-6 deficiency in tg SOD1
G93A
; caspase-6
-/- 
mice resulted in a decrease in survival 
compared to tg SOD1
G93A
; caspase-6
+/+
 (Figure 4.11) and motor function performance 
(Figures 4.6-4.10). In skeletal muscle, we compared weight and morphology of 
gastrocnemius muscle in SOD1
G93A 
mice and showed that deletion of caspase-6 does not 
affect muscular atrophy in this mouse model for ALS.  
Our initial hypothesis was that deletion of caspase-6 would protect neurons against cell death 
and therefore improve the phenotype in the SOD1
G93A
 ALS mouse model. However we found 
the opposite were true and that deletion of caspase-6 enhanced disease progression and 
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decreased lifespan. This suggests that caspase-6 plays a crucial role in neuronal survival 
possibly via cell removal of damaged cells, for instance cells that have been damaged by 
ROS caused by SOD1 toxicity. It is possible that caspase-6 may be pivotal in the regulation 
of cell death decisions within damaged cells and may be necessary to prevent damage to 
neighbouring cells. It has been proposed that caspase-6 demonstrates an unrecognized 
extracellular role and is released from axonal terminals, regulates microglial TNF-α secretion, 
synaptic plasticity, and inflammatory pain and may have a beneficial role in neuropathy 
(Berta et al. 2014). This evidence supports our hypothesis that this executioner caspase is 
protective during ALS pathogenesis as the degenerative phenotype is worse when caspase-6 
is removed, however further work is required to fully characterise the role of caspase-6. 
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CHAPTER 5 
 Discussion 
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5.1 Caspase-6 and ALS 
ALS is a neurodegenerative disease that is both progressive and incurable, with an incidence 
of 2-3 cases per 100,000 annually. The degeneration of motorneurons is key to the 
progression of the disease, resulting in muscle weakness and atrophy. For ALS, median 
survival time is typically 2-3 years post diagnosis. Significant data has been published since 
French neurologist Jean-Martin Charcot first described the progressive and fatal paralysis 
now known as ALS in 1869, yet the principle mediators of ALS remain elusive. Although the 
more recent development of the SOD1
G93A
 mouse model of ALS has been beneficial to 
understanding the disease, in the past 3-4 years substantial advances have been made to 
identify other genes involved in ALS disease pathophysiology. This advancement has 
resulted in the development of additional mouse models including FUS and TARDBP 
(known as TDP-43) mice (reviwed in Leblond et al., 2014). Despite the recent genetic 
advances in addition to decades of research, no cure has been discovered for ALS. Causative 
factors which culminate in ALS have been identified including, glial cell pathology, 
glutamate excitotoxicity, growth factor deprivation, caspase mediated cell death, defects in 
axonal transport, mitochondrial dysfunction, oxidative damage and accumulation of 
intracellular aggregates (Pasinelli and Brown, 2006). Recent in vivo studies have shown that 
deletion of caspase-6 prevents axonal degeneration (Uribe et al. 2012).  We hypothesized that 
if we remove caspase-6 in the SOD1
G93A
 mouse we may be able to prevent axonal 
degeneration and delay disease onset and progression. To assess this we generated a cross-
bred colony to examine the effect of caspase-6 deficiency on motor function and survival in 
the SOD1
G93A
 ALS mouse model. However, surprisingly we found that elimination of 
caspase-6 significantly exacerbated the symptoms and decreased the lifespan of SOD1
G93A
 
mice. There are several reasons why this may be occurring. One explanation is that caspase-6 
may be involved regulating cell removal of damaged cells, for instance cells that have been 
damaged by ROS caused by SOD1 toxicity. It is also possible that caspase-6 has a protective 
role that has not been characterized yet but which is evidenced by the degenerative phenotype 
which was increased when caspase-6 was removed.  
5.2 The role of apoptosis in Amyotrophic Lateral Sclerosis 
Apoptosis is central to the maintenance of cellular homeostasis, during embryonic 
development and for the removal of diseased or damaged cells in the body. In vivo studies on 
the effects of caspase deficiencies in mice have shown embryonic lethality for caspase-9 
deletion and also when caspase-3 is removed but is strain dependent, whereas caspase-6 
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removal does not demonstrate an overtly altered phenotype (Kuida et al. 1996; Hakem et al. 
1998). Understanding the apoptotic pathway is important for the study of diseases where 
excessive or insufficient cell death may play a part in disease pathogenesis. It has been 
suggested that caspase-6 may have an upstream role in the pathogenesis of neurodegenerative 
diseases (Graham et al. 2011) and may be a possible therapeutic target in neurodegenerative 
disease. 
The primary pathogenic processes underlying MND are likely to be multifactorial, and the 
precise mechanisms underlying the cell death pathway are still unknown. Programmed cell 
death and caspase activation has been commonly studied as apoptotic dysfunction is a 
potential mediator for ALS disease progression. In the spinal cord of SOD1
G93A 
mice, 
caspase-1 and caspase-3 expression and activation was shown to increase in symptomatic 
mice (Li et al. 2000). Caspase-9 is suggested to play a crucial role in the pathogenesis of ALS 
(Inoue et al., 2003) and activation has been detected in transgenic ALS mouse models 
(Guegan et al., 2001). Other evidence incudes a study completed by Tokuda et al., that 
identified Caspase-3, -8 and -9 upregulation and activation in the spinal cord of transgenic 
SOD1 mice at 8 and 16 weeks (Tokuda et al. 2007). Further work in vitro has demonstrated 
that under unstressed basal culture conditions, mutant SOD1 containing cells appear to be 
„„primed‟‟ for apoptosis as evidenced by increased amounts of phosphatidyl serine that are 
expressed on the cell surface and increased cleavage and activation of the initiator caspase-9 
compared to control cells (Sathasivam, S. et al. 2005). 
Several studies have shown neuronal caspase-6 activity is involved in axonal degeneration in 
vivo (Nickolaev et al. 2009; Simon et al. 2012; Uribe et al. 2012). We reason that caspase-6 
may be involved in the phenomenon known as the “dying-back” hypothesis which shows a 
distal to proximal axonal degeneration in the SOD1
G93A 
mouse model (Dadon-Nacum et al. 
2011). This lead to the theory that motor unit loss and associated muscle function may 
precede motorneuron death (Fischer et al. 2004; Vinsant et al. 2013). In mouse models for 
ALS, muscle denervation has been shown to occur months before motorneuron death (Frey et 
al. 2000; Fischer et al. 2004; Gould et al. 2006; Pun et al. 2006). There are few studies of this 
issue in humans, but it appears that denervation also corresponds to early symptom onset in 
ALS patients (Ag-garwal and Nicholson, 2002; Fischer et al. 2004; Blijham et al. 2007). The 
speciﬁc molecular mechanisms mediating axon/synapse loss in ALS are unknown, but it has 
been suggested that mutant SOD1 may alter retrograde transport and synaptic stability by 
disrupting the cytoplasmic dynein motor in motorneurons (Ligon et al. 2005). Additional 
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evidence can be seen in a study that utilized the Loa (Legs at odd angle) mice that have a 
mutation in cytoplasmic dynein (Kieran et al. 2005) crossed with in the SOD1
G93A
 mouse 
model, which showed that inhibition of retrograde transport may be protective, perhaps by 
inhibiting the transport of toxic negative signals (Ilieva et al. 2008). Similarly, one theory 
suggests an aggregation of insoluble complexes, possibly mutant SOD1, which causes an 
insufficient maintenance of the distal axon and results in axonal abnormalities that inhibit 
retrograde transport and allow for selective damage to motor neurons (Dadon-Nacum et al. 
2011).  
Caspase-6 cleavage of proteins in AD and HD promotes neurodegeneration by producing 
small toxic fragments of proteins (Galvan et al. 2006; Graham et al. 2006). It should be noted 
that, although compelling, evidence for AD and HD pathology provided by Galvan et al. and 
Graham et al. remains controversial due to conflicting data that was recently published. 
Harris et al. demonstrated through extensive neuronal and behavioral testing that impairment 
in transgenic mouse models of AD with mutations at the D664 site are independent of 
caspase cleavage of the amyloid precursor protein and inhibition of these mutations may have 
a lesser benefit than previously reported (Harris et al. 2010). In HD, it has been hypothesized 
that proteolysis of Htt at the caspase-6 cleavage site, amino acid Asp-586, plays a critical role 
in disease progression and pathogenesis (Hermel et al. 2004). Gafni et al. showed through in 
vivo studies utilizing caspase-6
-/-
 mice that contradict this hypothesis but caspase-6 may have 
a role in clearance pathways for mHtt protein (Gafni et al. 2012). It is not likely activated 
caspase-6 triggers neurodegeneration by cleavage of one specific protein due to the fact that 
caspase-6 has a high number of protein substrates in neurons (Petzke et al. 2006). It has also 
been shown that caspase-6 has a unique substrate, lamin A/C, which is not cleaved by either 
caspase-3 or caspase-7 (Takahashi et al. 1996). Other substrates have been identified in 
degeneration including AT-rich binding protein-1 (SATB1) in apoptosis (Galande, S. et al. 
2001), the neurodegenerative disease proteins Huntingtin (Graham et al. 2006) in HD, and 
amyloid precursor protein in AD (Pellegrini et al. 1999). It is possible that SOD1 could be a 
substrate unique to caspase-6 which may play a role in the degenerated phenotype in caspase-
6 deficient SOD1
G93A
 mice, but further work is necessary to provide evidence for this 
hypothesis.  
It has been suggested that caspase-6 exhibits an atypical role from executioner protease 
(Graham et al. 2011), and demonstrates the ability to self-activate (Klaiman et al. 2008), 
therefore it is possible that caspase-6 may have a role in the regulation of toxic cells through 
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self-activated pathway that has not yet been identified. It has been proposed that caspase-6 
has an extracellular role in signalling or eliciting an inflammatory response via TNF-α which 
may be protective, therefore it is possible that when caspase-6 is inhibited, protection against 
inflammation is decreased and the phenotype is exacerbated. Supporting this theory is a study 
completed by Berta et al. which showed that caspase-6 released from axonal terminals 
regulates microglial TNF-α secretion, synaptic plasticity, and inflammatory pain in vivo 
(Berta et al. 2014).  
 
5.3 The role of caspase-6 in neurodegenerative disease 
Increased apoptosis is associated with several neurodegenerative conditions like AD and HD 
(Okouchi et al. 2007). It has been hypothesized that caspase-6 has a role in disease pathology 
for ALS, and other neurodegenerative diseases. Active caspase-6 was discovered in post 
mortem brains of HD and AD subjects that did not have an apoptotic morphology, which 
suggests an alternative earlier function for caspase-6 other than an effector caspase (Albrecht 
et al. 2007, Graham et al. 2010) although this data is controversial. Studies have shown that 
active caspase-6 may contribute to the generation of AD pathology by evidence of increased 
production of Aβ in primary cultures of human neurons, as well as caspase-6 cleavage of tau 
and several synaptic proteins (LeBlanc et al. 1999, Albrecht et al, 2007). Through the use of 
a yeast artificial chromosome (YAC) model of HD, it was shown that expression of a 
mutation that eliminates cleavage at aa 586 of mutant Huntington (mhtt) by caspase-6 is 
sufficient to preserve striatal volume and cognitive and motor function (Graham et al. 2010). 
This evidence supports the theory that caspase-6 contributes negatively to neurodegeneration, 
but we have demonstrated that caspase-6 may provide a protective element in ALS.  
Our data shows caspase-6 levels were elevated at endstage of the disease in SOD1
G93A
 
lumbar spinal cord and hypothesize that there is an increase in microglia at endstage of the 
disease.  We were unable to locate pro or active caspase-6 in tg and ntg SOD1
G93A
 skeletal 
muscle via immunohistochemical analysis (data not shown), but we found no evidence for 
alteration at the neuromuscular junction leading us to suggest that the beneficial role of 
caspase-6 occurs in the CNS. As such, our data suggests that the beneficial role of caspase-6 
observed here may occur in other neurodegenerative diseases and caution should be exercised 
when investigating novel therapeutics targeting caspase-6. 
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5.4 Summary and Outlook 
Riluzole is the only Food and Drug Administration (FDA)-approved treatment that is 
available to ALS patients and only extends the life of some ALS patients by 3-6 months 
while alleviating associated symptoms (Miller et al. 2007; Bellingham, 2011).  Presently, 
there are no drugs on the market that reverse the disease. Successful inhibition of caspase-6 is 
an attainable goal since enzymes can be inhibited in several ways; they are viable targets for 
drug development. There are no known endogenous protein inhibitors of caspase-6 
(Edigington et al. 2013). Phosphorylation is also an inhibitor of caspase-6 (Velazques-
Delgado and Hardy, 2012).  In addition, it has been reported that inhibitor of apoptosis 
protein (IAP) that inhibit active caspase-3, caspase-7, and caspase-9 do not inhibit caspase-6 
(Deveraux and Roy et al. 1998). The use of zinc has been suggested as a potential inhibitor of 
selective caspase-6 due to its allosteric binding site that is unique to caspase-6, as the residues 
involved in zinc binding are not conserved across the caspase family (Velazques-Delgado and 
Hardy, 2012). It is important to note that no obvious developmental defects were initially 
discovered when the caspase deficient mouse was first developed (Zandy et al. 2005), but 
further studies have identified age-dependent and region-specific changes in the brains of 
caspase-6 deficient mice (Uribe et al. 2012). In order to most effectively target apoptosis in 
ALS, it is necessary to gain more information regarding the consequences of inhibition of 
caspase-6 as well as upstream activators of apoptosis in neurodegenerative diseases. Our data 
suggests that caspase-6 has a beneficial role in preventing disease progression in the 
SOD1
G93A
 ALS mouse model and is therefore not a good target for novel therapeutics. 
Based on our experiments, we conclude that genetic ablation of caspase-6 in the SOD1
G93A
 
mouse significantly affects motor function performance and survival, although molecular 
mechanisms are not fully understood. We cannot exclude the amelioration of additional 
parameters, for instance pre-symptomatic axonal abnormalities that inhibit retrograde 
transport and allow for selective damage to motor neurons. Future experiments to identify the 
role of caspase-6 may include a comparative behavioural study between caspase-3 and 
caspase-6 deficient mice crossed with other ALS mouse models for instance, TDP-43. A 
proteomic study would also be salient to determine if SOD1 is substrate of caspase-6. Other 
beneficial data regarding SOD1
G93A
; caspase-6 cross-breed may include motorneuron counts 
compared to muscle denervation at different stages of ALS disease progression to determine 
the potential order and location of apoptotic events. A better understanding of the neuronal 
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death pathways may provide targets for the development of therapeutic interventions for ALS 
and other neurodegenerative diseases.  
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